#Chr	Start	End	Ref	Alt	Ref.Gene	Func.refGene	ExonicFunc.refGene	Gene.ensGene	avsnp147	AAChange.ensGene	AAChange.refGene	clinvar: Clinvar 	 CancerVar: CancerVar and Evidence 	Freq_ExAC_ALL	Freq_esp6500siv2_all	Freq_1000g2015aug_all	Freq_gnomAD_genome_ALL	CADD_raw	CADD_phred	SIFT_score	GERP++_RS	phastCons20way_mammalian	dbscSNV_ADA_SCORE	dbscSNV_RF_SCORE	Interpro_domain	AAChange.knownGene	MetaSVM_score	Freq_gnomAD_genome_POPs	OMIM	Phenotype_MIM	OrphaNumber	Orpha	Pathway	Therap_list	Diag_list	Prog_list	Polyphen2_HDIV_score	FATHMM_score	MetaLR_score	MutationAssessor_score	Otherinfo
14	105246458	105246458	G	A	AKT1	exonic	nonsynonymous SNV	ENSG00000142208	rs374093099	ENSG00000142208:ENST00000554581:exon2:c.C142T:p.R48C,ENSG00000142208:ENST00000402615:exon3:c.C142T:p.R48C,ENSG00000142208:ENST00000407796:exon3:c.C142T:p.R48C,ENSG00000142208:ENST00000554848:exon3:c.C142T:p.R48C,ENSG00000142208:ENST00000555528:exon3:c.C142T:p.R48C,ENSG00000142208:ENST00000349310:exon4:c.C142T:p.R48C,ENSG00000142208:ENST00000555926:exon4:c.C142T:p.R48C	AKT1:NM_001014431:exon3:c.C142T:p.R48C,AKT1:NM_005163:exon3:c.C142T:p.R48C,AKT1:NM_001014432:exon4:c.C142T:p.R48C	clinvar: Uncertain_significance 	 CancerVar: 4#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, -1, 1, 1] 	5.819e-05	7.7e-05	.	3.23e-05	3.439	23.0	0.078	-1.99	0.116	.	.	Pleckstrin homology domain;Pleckstrin homology-like domain	AKT1:uc001ypl.3:exon2:c.C142T:p.R48C,AKT1:uc001ypk.3:exon3:c.C142T:p.R48C,AKT1:uc001ypn.3:exon3:c.C142T:p.R48C,AKT1:uc010axa.3:exon3:c.C142T:p.R48C,AKT1:uc001ypm.3:exon4:c.C142T:p.R48C	-0.968	AFR:0,AMR:0,EAS:0,FIN:0,NFE:6.668e-05,OTH:0,ASJ:0	164730	114480;114500;167000;176920;181500;615109;	201;744;227535;	201|Cowden disease<br>Multiple hamartoma syndrome|1-9 / 1 000 000|Autosomal dominant|All ages|158350 612359 615106 615107 615108 615109 616858 ~744|Partial gigantism-nevi-hemihypertrophy-macrocephaly syndrome|<1 / 1 000 000|Not applicable|Infancy|176920 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04022 cGMP-PKG signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04071 Sphingolipid signaling pathway~ko04072 Phospholipase D signaling pathway~ko04140 Autophagy - animal~ko04150 mTOR signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04152 AMPK signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04212 Longevity regulating pathway - worm~ko04213 Longevity regulating pathway - multiple species~ko04218 Cellular senescence~ko04261 Adrenergic signaling in cardiomyocytes~ko04370 VEGF signaling pathway~ko04371 Apelin signaling pathway~ko04380 Osteoclast differentiation~ko04510 Focal adhesion~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04611 Platelet activation~ko04620 Toll-like receptor signaling pathway~ko04625 C-type lectin receptor signaling pathway~ko04630 JAK-STAT signaling pathway~ko04660 T cell receptor signaling pathway~ko04662 B cell receptor signaling pathway~ko04664 Fc epsilon RI signaling pathway~ko04666 Fc gamma R-mediated phagocytosis~ko04668 TNF signaling pathway~ko04722 Neurotrophin signaling pathway~ko04725 Cholinergic synapse~ko04728 Dopaminergic synapse~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04915 Estrogen signaling pathway~ko04917 Prolactin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko04920 Adipocytokine signaling pathway~ko04922 Glucagon signaling pathway~ko04923 Regulation of lipolysis in adipocytes~ko04926 Relaxin signaling pathway~ko04929 GnRH secretion~ko04931 Insulin resistance~ko04932 Non-alcoholic fatty liver disease (NAFLD)~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko04973 Carbohydrate digestion and absorption~ko05135 Yersinia infection~ko05142 Chagas disease (American trypanosomiasis)~ko05145 Toxoplasmosis~ko05152 Tuberculosis~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05162 Measles~ko05163 Human cytomegalovirus infection~ko05164 Influenza A~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05169 Epstein-Barr virus infection~ko05170 Human immunodeficiency virus 1 infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05222 Small cell lung cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~ko05418 Fluid shear stress and atherosclerosis~	,393,392,391,390,396,395,394	.	.	0.626	0.53	0.133	1.15	lung
5	112175218	112175221	AAAG	-	APC	exonic	frameshift deletion	ENSG00000134982	.	ENSG00000134982:ENST00000257430:exon16:c.3927_3930del:p.E1309fs,ENSG00000134982:ENST00000457016:exon16:c.3927_3930del:p.E1309fs,ENSG00000134982:ENST00000508376:exon17:c.3927_3930del:p.E1309fs	APC:NM_001127511:exon14:c.3873_3876del:p.E1291fs,APC:NM_000038:exon16:c.3927_3930del:p.E1309fs,APC:NM_001127510:exon17:c.3927_3930del:p.E1309fs	clinvar: UNK 	 CancerVar: 8#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 0, 1, 0, 1, 2] 	.	.	.	.	.	.	.	.	.	.	.	.	APC:uc010jca.3:exon3:c.1827_1830del:p.E609fs,APC:uc011cvt.2:exon14:c.3873_3876del:p.E1291fs,APC:uc003kpy.4:exon16:c.3927_3930del:p.E1309fs,APC:uc003kpz.4:exon17:c.3927_3930del:p.E1309fs,APC:uc010jbz.3:exon17:c.3078_3081del:p.E1026fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	611731	114500;114550;135290;175100;613659;	220460;247806;733;79665;99818;873;449;88673;	220460|AFAP<br>Attenuated FAP<br>Attenuated familial polyposis coli|-|Autosomal dominant<br>or&nbsp;Autosomal recessive|Adult|175100 608456 612591 615083 616415 ~247806|APC-related AFAP<br>APC-related attenuated FAP<br>APC-related attenuated familial polyposis coli|-|Autosomal dominant<br>or&nbsp;Autosomal recessive|-|175100 ~733|Colorectal adenomatous polyposis<br>FAP<br>Familial polyposis coli|1-9 / 100 000|Autosomal dominant<br>or&nbsp;Autosomal recessive|Adult|175100 ~79665|-|-|-|-|175100 ~99818|-|-|Autosomal dominant|All ages|175100 ~873|Aggressive fibromatosis<br>Desmoid type fibromatosis|Unknown|Not applicable<br>or&nbsp;Unknown|Adolescent<br>Adult|135290 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~	~ko04310 Wnt signaling pathway~ko04390 Hippo signaling pathway~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04810 Regulation of actin cytoskeleton~ko04934 Cushing syndrome~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05213 Endometrial cancer~ko05217 Basal cell carcinoma~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	740,,742,743,745,737,739,738	.	,741	.	.	.	.	Colorectal
X	47426121	47426121	C	G	ARAF	exonic	nonsynonymous SNV	ENSG00000078061	.	ENSG00000078061:ENST00000377045:exon7:c.C641G:p.S214C	ARAF:NM_001256196:exon7:c.C650G:p.S217C,ARAF:NM_001654:exon7:c.C641G:p.S214C	clinvar: Likely_pathogenic 	 CancerVar: 8#Likely_pathogenic EVS=[1, 0, 0, 1, 0, 0, 1, 1, 0, 2, 1, 1] 	.	.	.	.	5.211	25.6	0.0	5.37	0.994	.	.	.	ARAF:uc004dic.2:exon7:c.C650G:p.S217C,ARAF:uc011mlo.3:exon7:c.C239G:p.S80C,ARAF:uc011mlp.3:exon7:c.C641G:p.S214C	0.336	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	311010	.	.	.	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04068 FoxO signaling pathway~ko04270 Vascular smooth muscle contraction~ko04650 Natural killer cell mediated cytotoxicity~ko04720 Long-term potentiation~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04928 Parathyroid hormone synthesis, secretion and action~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	,768,769,770,763,766,767,764,765	.	.	0.997	-1.08	0.610	2.415	lung
1	27101273	27101273	-	C	ARID1A	exonic	frameshift insertion	ENSG00000117713	.	ENSG00000117713:ENST00000374152:exon17:c.3406dupC:p.Q1136fs,ENSG00000117713:ENST00000324856:exon18:c.4555dupC:p.Q1519fs	ARID1A:NM_006015:exon18:c.4555dupC:p.Q1519fs	clinvar: UNK 	 CancerVar: 6#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 1, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	ARID1A:uc001bmx.1:exon7:c.1093dupC:p.Q365fs,ARID1A:uc001bmw.1:exon17:c.3406dupC:p.Q1136fs,ARID1A:uc001bmt.1:exon18:c.4552dupC:p.Q1518fs,ARID1A:uc001bmv.1:exon18:c.4555dupC:p.Q1519fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	603024	614607;	1465;	1465|CSS|<1 / 1 000 000|Autosomal dominant|Neonatal|135900 614607 614608 614609 615866 616938 ~	.	,809,808,810,811,812,807,806,805,804	.	.	.	.	.	.	bladder
11	108117798	108117798	C	T	ATM	exonic	nonsynonymous SNV	ENSG00000149311	rs138398778	ENSG00000149311:ENST00000278616:exon8:c.C1009T:p.R337C,ENSG00000149311:ENST00000527805:exon8:c.C1009T:p.R337C,ENSG00000149311:ENST00000452508:exon9:c.C1009T:p.R337C	ATM:NM_000051:exon8:c.C1009T:p.R337C	clinvar: Uncertain_significance 	 CancerVar: 9#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 0, 2, 1, 1, 1] 	9.091e-05	7.7e-05	.	0.0001	7.645	35	0.0	5.72	0.997	.	.	Armadillo-type fold	ATM:uc001pkb.1:exon8:c.C1009T:p.R337C,ATM:uc009yxr.1:exon9:c.C1009T:p.R337C	-1.234	AFR:0.0001,AMR:0,EAS:0,FIN:0,NFE:0.0002,OTH:0,ASJ:0	607585	114480;208900;	100;227535;	100|Louis-Bar syndrome|1-9 / 1 000 000|Autosomal recessive|Infancy<br>Childhood|208900 208910 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01524 Platinum drug resistance~ko03440 Homologous recombination~ko04064 NF-kappa B signaling pathway~ko04068 FoxO signaling pathway~ko04110 Cell cycle~ko04115 p53 signaling pathway~ko04210 Apoptosis~ko04214 Apoptosis - fly~ko04218 Cellular senescence~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05170 Human immunodeficiency virus 1 infection~ko05202 Transcriptional misregulation in cancer~ko05206 MicroRNAs in cancer~	902,903,900,893,894,895,904,898,877,908,909,,901,899,906,912,911,910,907	.	,896,897	1.0	4.62	0.037	2.095	Colorectal
X	76890149	76890149	-	A	ATRX	exonic	frameshift insertion	ENSG00000085224	.	ENSG00000085224:ENST00000395603:exon16:c.4630_4631insT:p.T1544fs,ENSG00000085224:ENST00000373344:exon17:c.4744_4745insT:p.T1582fs	ATRX:NM_138270:exon16:c.4630_4631insT:p.T1544fs,ATRX:NM_000489:exon17:c.4744_4745insT:p.T1582fs	clinvar: UNK 	 CancerVar: 4#Uncertain_significance EVS=[0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 1, 0] 	.	.	.	.	.	.	.	.	.	.	.	.	ATRX:uc004ecq.4:exon16:c.4630_4631insT:p.T1544fs,ATRX:uc004ecp.4:exon17:c.4744_4745insT:p.T1582fs,ATRX:uc004eco.4:exon18:c.4099_4100insT:p.T1367fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	300504	.	.	.	.	.	933,	.	.	.	.	.	brain
15	45007635	45007635	C	T	B2M	exonic	stopgain	ENSG00000166710	.	ENSG00000166710:ENST00000544417:exon2:c.C82T:p.Q28X,ENSG00000166710:ENST00000558401:exon2:c.C82T:p.Q28X,ENSG00000166710:ENST00000559720:exon2:c.C82T:p.Q28X,ENSG00000166710:ENST00000559916:exon2:c.C82T:p.Q28X,ENSG00000166710:ENST00000561424:exon2:c.C82T:p.Q28X	B2M:NM_004048:exon2:c.C82T:p.Q28X	clinvar: UNK 	 CancerVar: 6#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 1, 0, 1, 1] 	.	.	.	.	10.932	37	.	5.82	0.154	.	.	Immunoglobulin-like domain;Immunoglobulin-like fold	B2M:uc001zuc.3:exon2:c.C82T:p.Q28X,B2M:uc010bdx.1:exon2:c.C82T:p.Q28X,B2M:uc010uek.1:exon2:c.C82T:p.Q28X	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	109700	105200;241600;	85450;	85450|Amyloidosis, Ostertag type<br>Familial amyloid nephropathy<br>Familial renal amyloidosis<br>Hereditary amyloid nephropathy<br>Hereditary renal amyloidosis|Unknown|Autosomal dominant|All ages|105200 ~	.	,942	.	.	.	.	.	.	Esophagus
7	140453154	140453154	T	C	BRAF	exonic	nonsynonymous SNV	ENSG00000157764	rs121913338	ENSG00000157764:ENST00000479537:exon2:c.A65G:p.D22G,ENSG00000157764:ENST00000288602:exon15:c.A1781G:p.D594G	BRAF:NM_004333:exon15:c.A1781G:p.D594G	clinvar: Pathogenic 	 CancerVar: 12#Pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 2] 	.	.	.	.	6.419	29.7	0.002	5.65	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain	BRAF:uc003vwc.4:exon15:c.A1781G:p.D594G	0.452	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164757	115150;211980;613706;613707;	500;648;1340;	500|Cardiomyopathic lentiginosis<br>Familial multiple lentigines syndrome<br>LEOPARD syndrome|Unknown|Autosomal dominant|Childhood|151100 611554 613707 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04150 mTOR signaling pathway~ko04214 Apoptosis - fly~ko04270 Vascular smooth muscle contraction~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04650 Natural killer cell mediated cytotoxicity~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	1227,1165,1166,1167,1209,1208,1221,1213,1200,1204,1207,1206,1168,1169,1203,1202,1174,1216,1225,,1217,1199,1198,1215,1214,1191,1190,1193,1192,1195,1194,1197,1196,1220,1205,1224,1015,1016,1218,1013,1177,1176,1175,996,1173,1172,1171,1170,1201,1211,1219,999,1179,1178,1014,1229,1223,1228,1188,1189,1186,1187,1184,1185,1182,1183,1180,1181,1212,1011,1222,1246,1210,1226	.	,1230,1231,1232,1012	0.994	-7.18	0.603	3.565	skin
7	140481412	140481412	C	G	BRAF	exonic	nonsynonymous SNV	ENSG00000157764	rs121913353	ENSG00000157764:ENST00000288602:exon11:c.G1396C:p.G466R	BRAF:NM_004333:exon11:c.G1396C:p.G466R	clinvar: UNK 	 CancerVar: 9#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 0, 1, 2, 1, 1] 	.	.	.	.	6.779	32	0.0	5.62	0.995	.	.	Protein kinase domain;Protein kinase, ATP binding site;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain	BRAF:uc003vwc.4:exon11:c.G1396C:p.G466R	0.921	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164757	115150;211980;613706;613707;	500;648;1340;	500|Cardiomyopathic lentiginosis<br>Familial multiple lentigines syndrome<br>LEOPARD syndrome|Unknown|Autosomal dominant|Childhood|151100 611554 613707 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04150 mTOR signaling pathway~ko04214 Apoptosis - fly~ko04270 Vascular smooth muscle contraction~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04650 Natural killer cell mediated cytotoxicity~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	1227,1165,1166,1167,1209,1208,1221,1213,1200,1204,1207,1206,1168,1169,1203,1202,1174,1216,1225,,1217,1199,1198,1215,1214,1191,1190,1193,1192,1195,1194,1197,1196,1220,1205,1224,1218,1177,1176,1175,996,1173,1172,1171,1170,1201,1211,1219,1179,1178,1229,1223,1228,1188,1189,1186,1187,1184,1185,1182,1183,1180,1181,1212,1222,1246,1210,1226	.	,1230,1231,1232	0.999	-8.16	0.998	4.475	Kidney
7	140453109	140453109	T	A	BRAF	exonic	nonsynonymous SNV	ENSG00000157764	.	ENSG00000157764:ENST00000479537:exon2:c.A110T:p.Q37L,ENSG00000157764:ENST00000288602:exon15:c.A1826T:p.Q609L	BRAF:NM_004333:exon15:c.A1826T:p.Q609L	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[1, 0, 1, 1, 0, 0, 1, 0, 0, -1, 1, 1] 	.	.	.	.	5.027	25.2	0.003	5.65	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain	BRAF:uc003vwc.4:exon15:c.A1826T:p.Q609L	-0.921	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164757	115150;211980;613706;613707;	500;648;1340;	500|Cardiomyopathic lentiginosis<br>Familial multiple lentigines syndrome<br>LEOPARD syndrome|Unknown|Autosomal dominant|Childhood|151100 611554 613707 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04150 mTOR signaling pathway~ko04214 Apoptosis - fly~ko04270 Vascular smooth muscle contraction~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04650 Natural killer cell mediated cytotoxicity~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	1227,1165,1166,1167,1209,1208,1221,1213,1200,1204,1207,1206,1168,1169,1203,1202,1174,1216,1225,,1217,1199,1198,1215,1214,1191,1190,1193,1192,1195,1194,1197,1196,1220,1205,1224,1218,1177,1176,1175,996,1173,1172,1171,1170,1201,1211,1219,1179,1178,1229,1223,1228,1188,1189,1186,1187,1184,1185,1182,1183,1180,1181,1212,1222,1246,1210,1226	.	,1230,1231,1232	0.069	-1.65	0.152	0.38	breast
7	140453136	140453136	A	T	BRAF	exonic	nonsynonymous SNV	ENSG00000157764	rs113488022	ENSG00000157764:ENST00000479537:exon2:c.T83A:p.V28E,ENSG00000157764:ENST00000288602:exon15:c.T1799A:p.V600E	BRAF:NM_004333:exon15:c.T1799A:p.V600E	clinvar: Pathogenic 	 CancerVar: 14#Pathogenic EVS=[2, 1, 2, 1, 0, 0, 1, 1, 2, 1, 1, 2] 	1.65e-05	.	.	.	6.642	32	0.001	5.65	1.000	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain	BRAF:uc003vwc.4:exon15:c.T1799A:p.V600E	-0.768	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164757	115150;211980;613706;613707;	500;648;1340;	500|Cardiomyopathic lentiginosis<br>Familial multiple lentigines syndrome<br>LEOPARD syndrome|Unknown|Autosomal dominant|Childhood|151100 611554 613707 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04150 mTOR signaling pathway~ko04214 Apoptosis - fly~ko04270 Vascular smooth muscle contraction~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04650 Natural killer cell mediated cytotoxicity~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	,1200,1564,1565,1522,1566,1398,1490,1491,1492,1493,1494,1495,1496,1497,1498,1499,1567,1528,1529,1409,1408,1403,1402,1401,1400,1407,1406,1405,1404,1339,1338,1335,1334,1337,1336,1331,1330,1333,1332,1448,1458,1459,1537,1536,1535,1534,1533,1532,1531,1530,1539,1538,1623,1622,1621,1620,1627,1626,1624,1629,1628,1352,1519,1314,1199,1198,1518,1191,1190,1193,1192,1195,1194,1197,1196,1177,1176,1175,1174,1173,1172,1171,1170,1179,1178,1285,1284,1287,1286,1283,1282,1289,1288,1472,1473,1470,1471,1476,1477,1474,1475,1573,1572,1478,1479,1577,1576,1575,1574,1304,1305,1306,1307,1300,1301,1302,1303,1308,1309,1371,1370,1373,1372,1375,1374,1377,1376,1379,1378,1229,1228,1483,1482,1481,1480,1487,1486,1485,1484,1489,1488,1436,1437,1434,1432,1433,1431,1438,1439,1007,1006,1005,1004,1003,1002,1001,1000,1348,1226,1225,1224,1223,1222,1221,1220,1340,1341,1342,1343,1344,1345,1346,1347,1502,1503,1500,1501,1506,1507,1504,1505,1508,1509,1227,1618,1619,1616,1617,1614,1615,1612,1579,1610,1611,1578,1571,1570,1546,1547,1544,1545,1542,1543,1541,1548,1549,1469,1468,1465,1464,1467,1466,1461,1460,1463,1462,1317,1316,1315,996,1313,1312,1311,1310,1319,1318,1388,1389,1386,1387,1380,1381,1641,1643,1642,1421,1420,1423,1422,1425,1424,1427,1426,1428,1580,1581,1586,1587,1584,1585,1212,1213,1359,1358,1216,1217,1214,1215,1353,1168,1218,1219,1357,1356,1355,1169,1454,1455,1456,1457,1450,1451,1452,1453,1515,1514,1517,1516,1511,1510,1513,1512,1246,1609,1608,1601,1600,1602,1605,1604,1607,1606,1613,1568,1569,1298,1444,1561,1562,1551,1550,1553,1552,1555,1554,1557,1556,1559,1558,1297,1418,1419,1294,1410,1411,1412,1413,1414,1415,1416,1417,1322,1323,1320,1321,1326,1327,1324,1325,1328,1329,1524,1525,1526,1527,1520,1521,1399,1523,1397,1396,1395,1394,1393,1392,1391,1390,1588,1589,1583,1630,1631,1632,1633,1634,1595,1594,1597,1596,1591,1590,1593,1592,1599,1598,1188,1189,1186,1187,1184,1185,1182,1183,1180,1181,1349,1165,1166,1167,1209,1208,1205,1204,1207,1206,1201,1210,1203,1202,1211,1447,1446,1445,1299,1443,1442,1441,1440,1560,1293,1290,1291,1296,1351,1449,1295,1350,1354,1563,1366,1364,1365,1362,1363,1360,1361,1368,1369	1429,,1625,1430,1640	,1230,1231,1232,1637,1582,1639,1638,1367,1636,1635,1384,1385,1540,1382,1383	0.971	-1.53	0.236	1.32	Colorectal
13	32972626	32972626	A	T	BRCA2	exonic	stopgain	ENSG00000139618	rs11571833	ENSG00000139618:ENST00000380152:exon27:c.A9976T:p.K3326X,ENSG00000139618:ENST00000544455:exon27:c.A9976T:p.K3326X	BRCA2:NM_000059:exon27:c.A9976T:p.K3326X	clinvar: Benign 	 CancerVar: 6#Uncertain_significance EVS=[2, 0, 1, 1, 0, 0, 0, -1, 0, 0, 1, 2] 	0.0070	0.0065	0.00439297	0.0053	12.122	38	.	0.163	0.030	.	.	.	BRCA2:uc001uub.1:exon27:c.A9976T:p.K3326X	.	AFR:0.0019,AMR:0.0036,EAS:0,FIN:0.0097,NFE:0.0066,OTH:0.0102,ASJ:0.0066	600185	114480;155255;176807;194070;605724;612555;613029;613347;	1333;182067;360;145;227535;319462;654;1331;251858;251863;251867;616;227535;	1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~145|-|1-5 / 10 000|Autosomal dominant|All ages|604370 612555 613399 614291 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~319462|-|-|-|-|605724 ~654|Renal embryonic tumor<br>Wilms tumor|1-9 / 100 000|Autosomal dominant<br>or&nbsp;Not applicable|Childhood|194070 194071 194090 601363 601583 616806 ~1331|-|-|-|Adult|176807 300147 300704 601518 602759 603688 608656 608658 609299 609558 610321 610997 611100 611868 611928 611955 611958 611959 614731 ~251858|MBEN|-|Not applicable|Infancy<br>Childhood|155255 ~251863|-|-|Not applicable|Adult|155255 ~251867|-|-|-|Childhood|155255 ~616|-|1-9 / 100 000|Not applicable|All ages|155255 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko03440 Homologous recombination~ko03460 Fanconi anemia pathway~ko05200 Pathways in cancer~ko05212 Pancreatic cancer~ko05224 Breast cancer~	,1840,1845,1832,1833,1830,1831,1836,1837,1834,1835,1838,1839,1819,1829,1828,1825,1824,1827,1826,1820,1823,1844,1843,1842,1841	.	,1821,1822	.	.	.	.	breast
13	32954279	32954279	-	A	BRCA2	exonic	frameshift insertion	ENSG00000139618	.	ENSG00000139618:ENST00000380152:exon24:c.9253dupA:p.T3085fs,ENSG00000139618:ENST00000544455:exon24:c.9253dupA:p.T3085fs	BRCA2:NM_000059:exon24:c.9253dupA:p.T3085fs	clinvar: UNK 	 CancerVar: 6#Uncertain_significance EVS=[1, 0, 1, 1, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	BRCA2:uc001uub.1:exon24:c.9253dupA:p.T3085fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	600185	114480;155255;176807;194070;605724;612555;613029;613347;	1333;182067;360;145;227535;319462;654;1331;251858;251863;251867;616;227535;	1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~145|-|1-5 / 10 000|Autosomal dominant|All ages|604370 612555 613399 614291 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~319462|-|-|-|-|605724 ~654|Renal embryonic tumor<br>Wilms tumor|1-9 / 100 000|Autosomal dominant<br>or&nbsp;Not applicable|Childhood|194070 194071 194090 601363 601583 616806 ~1331|-|-|-|Adult|176807 300147 300704 601518 602759 603688 608656 608658 609299 609558 610321 610997 611100 611868 611928 611955 611958 611959 614731 ~251858|MBEN|-|Not applicable|Infancy<br>Childhood|155255 ~251863|-|-|Not applicable|Adult|155255 ~251867|-|-|-|Childhood|155255 ~616|-|1-9 / 100 000|Not applicable|All ages|155255 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko03440 Homologous recombination~ko03460 Fanconi anemia pathway~ko05200 Pathways in cancer~ko05212 Pancreatic cancer~ko05224 Breast cancer~	,1840,1845,1832,1833,1830,1831,1836,1837,1834,1835,1838,1839,1819,1829,1828,1825,1824,1827,1826,1820,1823,1844,1843,1842,1841	.	,1821,1822	.	.	.	.	prostate
13	32912414	32912414	G	T	BRCA2	exonic	stopgain	ENSG00000139618	rs80358638	ENSG00000139618:ENST00000380152:exon11:c.G3922T:p.E1308X,ENSG00000139618:ENST00000544455:exon11:c.G3922T:p.E1308X	BRCA2:NM_000059:exon11:c.G3922T:p.E1308X	clinvar: Pathogenic 	 CancerVar: 7#Uncertain_significance EVS=[1, 0, 1, 1, 0, 0, 1, 1, 0, 0, 1, 1] 	.	.	.	3.232e-05	9.604	36	.	3.13	0.159	.	.	.	BRCA2:uc001uub.1:exon11:c.G3922T:p.E1308X	.	AFR:0,AMR:0.0012,EAS:0,FIN:0,NFE:0,OTH:0,ASJ:0	600185	114480;155255;176807;194070;605724;612555;613029;613347;	1333;182067;360;145;227535;319462;654;1331;251858;251863;251867;616;227535;	1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~145|-|1-5 / 10 000|Autosomal dominant|All ages|604370 612555 613399 614291 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~319462|-|-|-|-|605724 ~654|Renal embryonic tumor<br>Wilms tumor|1-9 / 100 000|Autosomal dominant<br>or&nbsp;Not applicable|Childhood|194070 194071 194090 601363 601583 616806 ~1331|-|-|-|Adult|176807 300147 300704 601518 602759 603688 608656 608658 609299 609558 610321 610997 611100 611868 611928 611955 611958 611959 614731 ~251858|MBEN|-|Not applicable|Infancy<br>Childhood|155255 ~251863|-|-|Not applicable|Adult|155255 ~251867|-|-|-|Childhood|155255 ~616|-|1-9 / 100 000|Not applicable|All ages|155255 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko03440 Homologous recombination~ko03460 Fanconi anemia pathway~ko05200 Pathways in cancer~ko05212 Pancreatic cancer~ko05224 Breast cancer~	,1840,1845,1832,1833,1830,1831,1836,1837,1834,1835,1838,1839,1819,1829,1828,1825,1824,1827,1826,1820,1823,1844,1843,1842,1841	.	,1821,1822	.	.	.	.	Adrenal_Gland
16	68842407	68842407	G	A	CDH1	exonic	stopgain	ENSG00000039068	.	ENSG00000039068:ENST00000261769:exon4:c.G468A:p.W156X,ENSG00000039068:ENST00000422392:exon4:c.G468A:p.W156X,ENSG00000039068:ENST00000566510:exon4:c.G468A:p.W156X,ENSG00000039068:ENST00000566612:exon4:c.G468A:p.W156X	CDH1:NM_001317184:exon4:c.G468A:p.W156X,CDH1:NM_004360:exon4:c.G468A:p.W156X	clinvar: Likely_pathogenic 	 CancerVar: 8#Likely_pathogenic EVS=[1, 1, 1, 1, 0, 0, 1, 1, 0, 0, 1, 1] 	.	.	.	.	11.357	37	.	5.87	1.000	.	.	Cadherin-like	CDH1:uc002ewg.1:exon4:c.G468A:p.W156X,CDH1:uc010cfg.1:exon4:c.G468A:p.W156X	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	192090	114480;137215;167000;176807;608089;	1331;26106;227535;	1331|-|-|-|Adult|176807 300147 300704 601518 602759 603688 608656 608658 609299 609558 610321 610997 611100 611868 611928 611955 611958 611959 614731 ~26106|FDGC<br>Familial diffuse cancer of stomach<br>Familial diffuse gastric cancer<br>HDGC<br>Hereditary diffuse cancer of stomach<br>Hereditary diffuse gastric adenocarcinoma|Unknown|Autosomal dominant|Adult|137215 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko04015 Rap1 signaling pathway~ko04371 Apelin signaling pathway~ko04390 Hippo signaling pathway~ko04514 Cell adhesion molecules (CAMs)~ko04520 Adherens junction~ko05100 Bacterial invasion of epithelial cells~ko05200 Pathways in cancer~ko05213 Endometrial cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05226 Gastric cancer~	,1948,1944,1945	,1946	,1947	.	.	.	.	breast
9	21971042	21971042	G	-	CDKN2A	exonic	frameshift deletion	ENSG00000147889	.	ENSG00000147889:ENST00000578845:exon1:c.163delG:p.V55fs,ENSG00000147889:ENST00000304494:exon2:c.316delG:p.V106fs,ENSG00000147889:ENST00000361570:exon2:c.482delG:p.R161fs,ENSG00000147889:ENST00000446177:exon2:c.316delG:p.V106fs,ENSG00000147889:ENST00000479692:exon2:c.163delG:p.V55fs,ENSG00000147889:ENST00000497750:exon2:c.163delG:p.V55fs,ENSG00000147889:ENST00000498124:exon2:c.316delG:p.V106fs,ENSG00000147889:ENST00000498628:exon2:c.163delG:p.V55fs,ENSG00000147889:ENST00000530628:exon2:c.359delG:p.R120fs,ENSG00000147889:ENST00000579122:exon2:c.316delG:p.V106fs,ENSG00000147889:ENST00000579755:exon2:c.359delG:p.R120fs,ENSG00000147889:ENST00000494262:exon3:c.163delG:p.V55fs	CDKN2A:NM_000077:exon2:c.316delG:p.V106fs,CDKN2A:NM_001195132:exon2:c.316delG:p.V106fs,CDKN2A:NM_058195:exon2:c.359delG:p.R120fs	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	CDKN2A:uc003zpk.3:exon2:c.316delG:p.V106fs,CDKN2A:uc003zpl.3:exon2:c.359delG:p.R120fs,CDKN2A:uc010miu.3:exon2:c.316delG:p.V106fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	600160	155601;155755;606719;	404560;252206;618;	404560|B-K mole syndrome<br>FAMM-PC syndrome<br>FAMMM syndrome<br>Familial Clark nevus syndrome<br>Familial atypical mole syndrome<br>Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome<br>Familial dysplastic nevus syndrome<br>Melanoma-pancreatic cancer syndrome|Unknown|Autosomal dominant|Childhood<br>Adolescent<br>Adult|155600 606719 ~252206|Melanoma-astrocytoma syndrome|-|Autosomal dominant<br>or&nbsp;Unknown|-|155755 ~618|-|Unknown|Autosomal dominant<br>or&nbsp;Multigenic/multifactorial|Adult|155600 155601 155700 608035 609048 613099 613972 615134 615848 ~	~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04110 Cell cycle~ko04115 p53 signaling pathway~ko04218 Cellular senescence~ko04934 Cushing syndrome~ko05163 Human cytomegalovirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05200 Pathways in cancer~ko05203 Viral carcinogenesis~ko05206 MicroRNAs in cancer~ko05212 Pancreatic cancer~ko05214 Glioma~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05223 Non-small cell lung cancer~ko05225 Hepatocellular carcinoma~	,2002,2003,2000,2001,2004,2009,2011,2010,2013,2012	.	.	.	.	.	.	Nervous_System
11	125513687	125513687	G	A	CHEK1	exonic	nonsynonymous SNV	ENSG00000149554	.	ENSG00000149554:ENST00000278916:exon8:c.G815A:p.G272E,ENSG00000149554:ENST00000427383:exon8:c.G863A:p.G288E,ENSG00000149554:ENST00000524737:exon8:c.G815A:p.G272E,ENSG00000149554:ENST00000428830:exon9:c.G815A:p.G272E,ENSG00000149554:ENST00000438015:exon9:c.G815A:p.G272E,ENSG00000149554:ENST00000534070:exon9:c.G815A:p.G272E,ENSG00000149554:ENST00000544373:exon9:c.G815A:p.G272E	CHEK1:NM_001114121:exon9:c.G815A:p.G272E,CHEK1:NM_001114122:exon9:c.G815A:p.G272E,CHEK1:NM_001244846:exon9:c.G815A:p.G272E,CHEK1:NM_001274:exon9:c.G815A:p.G272E	clinvar: UNK 	 CancerVar: 1#Benign/Likely_benign EVS=[0, 0, 0, 0, 0, 0, 1, 0, 0, -1, 1, 0] 	.	.	.	.	2.323	18.31	0.273	3.92	0.999	0.1959	0.526	Protein kinase domain;Protein kinase-like domain;Serine/threonine/dual specificity protein kinase, catalytic  domain	CHEK1:uc010sbh.2:exon8:c.G863A:p.G288E,CHEK1:uc001qcf.4:exon9:c.G815A:p.G272E,CHEK1:uc001qcg.4:exon9:c.G815A:p.G272E,CHEK1:uc009zbo.3:exon9:c.G815A:p.G272E,CHEK1:uc009zbp.3:exon9:c.G815A:p.G272E,CHEK1:uc010sbi.2:exon9:c.G815A:p.G272E	-0.908	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	603078	.	.	.	~ko04110 Cell cycle~ko04111 Cell cycle - yeast~ko04113 Meiosis - yeast~ko04115 p53 signaling pathway~ko04218 Cellular senescence~ko05166 Human T-cell leukemia virus 1 infection~ko05170 Human immunodeficiency virus 1 infection~ko05203 Viral carcinogenesis~	.	.	.	0.002	-0.3	0.186	0.895	Bile_Duct
3	41277276	41277276	G	C	CTNNB1	exonic	nonsynonymous SNV	ENSG00000168036	.	ENSG00000168036:ENST00000349496:exon11:c.G1745C:p.R582P,ENSG00000168036:ENST00000396183:exon11:c.G1745C:p.R582P,ENSG00000168036:ENST00000396185:exon11:c.G1745C:p.R582P,ENSG00000168036:ENST00000405570:exon12:c.G1745C:p.R582P,ENSG00000168036:ENST00000453024:exon12:c.G1724C:p.R575P	CTNNB1:NM_001098209:exon11:c.G1745C:p.R582P,CTNNB1:NM_001098210:exon11:c.G1745C:p.R582P,CTNNB1:NM_001904:exon11:c.G1745C:p.R582P	clinvar: UNK 	 CancerVar: 8#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 0, 0, 2, 1, 1] 	.	.	.	.	7.658	35	0.002	5.62	0.999	.	.	Armadillo-like helical;Armadillo-type fold	CTNNB1:uc003ckt.1:exon1:c.G50C:p.R17P,CTNNB1:uc003ckp.2:exon11:c.G1745C:p.R582P,CTNNB1:uc003ckq.2:exon11:c.G1745C:p.R582P,CTNNB1:uc003ckr.2:exon11:c.G1745C:p.R582P,CTNNB1:uc011azg.1:exon11:c.G1529C:p.R510P,CTNNB1:uc010hia.1:exon12:c.G1745C:p.R582P,CTNNB1:uc011azf.1:exon12:c.G1724C:p.R575P	0.341	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	116806	114500;114550;132600;167000;615075;	404473;91414;449;88673;	404473|-|<1 / 1 000 000|Unknown|Infancy|615075 ~91414|Epithelioma calcificans of Malherbe<br>Pilomatricoma|Unknown|Not applicable|Childhood<br>Adolescent<br>Adult|132600 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~	~ko04015 Rap1 signaling pathway~ko04310 Wnt signaling pathway~ko04390 Hippo signaling pathway~ko04510 Focal adhesion~ko04520 Adherens junction~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04670 Leukocyte transendothelial migration~ko04916 Melanogenesis~ko04919 Thyroid hormone signaling pathway~ko04934 Cushing syndrome~ko05100 Bacterial invasion of epithelial cells~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05210 Colorectal cancer~ko05213 Endometrial cancer~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05217 Basal cell carcinoma~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05412 Arrhythmogenic right ventricular cardiomyopathy (ARVC)~ko05418 Fluid shear stress and atherosclerosis~	,2115,2119,2100,2099,2098,2116,2117	.	2118,	1.0	-0.21	0.602	3.365	skin
6	33288659	33288659	G	A	DAXX	exonic	nonsynonymous SNV	ENSG00000204209	.	ENSG00000204209:ENST00000414083:exon2:c.C668T:p.A223V,ENSG00000204209:ENST00000266000:exon3:c.C893T:p.A298V,ENSG00000204209:ENST00000374542:exon3:c.C893T:p.A298V	DAXX:NM_001254717:exon2:c.C668T:p.A223V,DAXX:NM_001141969:exon3:c.C893T:p.A298V,DAXX:NM_001141970:exon3:c.C929T:p.A310V,DAXX:NM_001350:exon3:c.C893T:p.A298V	clinvar: UNK 	 CancerVar: 1#Benign/Likely_benign EVS=[0, 0, 0, 0, 0, 0, 1, 0, 0, -1, 1, 0] 	.	.	.	.	1.805	15.02	0.251	2.81	0.910	.	.	.	DAXX:uc010juw.2:exon2:c.C668T:p.A223V,DAXX:uc011drd.2:exon2:c.C668T:p.A223V,DAXX:uc021ywn.1:exon2:c.C893T:p.A298V,DAXX:uc021ywo.1:exon2:c.C893T:p.A298V,DAXX:uc003oec.3:exon3:c.C893T:p.A298V,DAXX:uc003oed.3:exon3:c.C893T:p.A298V,DAXX:uc011dre.2:exon3:c.C929T:p.A310V	-1.079	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	603186	.	.	.	.	.	.	.	0.866	.	0.046	1.5	Pancreas
7	55242466	55242466	-	TTCCCGTCGCTATCAAGG	EGFR	exonic	nonframeshift insertion	ENSG00000146648	.	ENSG00000146648:ENST00000455089:exon18:c.2101_2102insTTCCCGTCGCTATCAAGG:p.E701delinsVPVAIKE,ENSG00000146648:ENST00000275493:exon19:c.2236_2237insTTCCCGTCGCTATCAAGG:p.E746delinsVPVAIKE,ENSG00000146648:ENST00000454757:exon19:c.2077_2078insTTCCCGTCGCTATCAAGG:p.E693delinsVPVAIKE	EGFR:NM_005228:exon19:c.2236_2237insTTCCCGTCGCTATCAAGG:p.E746delinsVPVAIKE	clinvar: UNK 	 CancerVar: 9#Likely_pathogenic EVS=[2, 0, 2, 0, 0, 0, 1, 0, 1, 0, 1, 2] 	.	.	.	.	.	.	.	.	.	.	.	.	EGFR:uc010kzg.2:exon18:c.2101_2102insTTCCCGTCGCTATCAAGG:p.E701delinsVPVAIKE,EGFR:uc022adn.1:exon18:c.2101_2102insTTCCCGTCGCTATCAAGG:p.E701delinsVPVAIKE,EGFR:uc003tqk.3:exon19:c.2236_2237insTTCCCGTCGCTATCAAGG:p.E746delinsVPVAIKE,EGFR:uc011kco.2:exon19:c.2077_2078insTTCCCGTCGCTATCAAGG:p.E693delinsVPVAIKE,EGFR:uc022adm.1:exon19:c.2236_2237insTTCCCGTCGCTATCAAGG:p.E746delinsVPVAIKE	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	2712,3247,3240,3259,,3258,3243,3255,3246,3245,3234,3222,3214,3215,3216,3217,3236,3211,3212,3213,3251,3238,3239,3218,3219,3256,3257,3252,3235,2509,2508,2507,2506,3262,2680,2681,2682,3232,3233,3230,3242,3261,3253,3263,3231,3265,3264,3267,3266,3269,3268,3244,3237,3248,3229,3228,3254,3260,3225,3224,3227,3226,3221,3220,3223,3370,2671,2670,2673,2672,2675,2674,2677,2676,2679,2678,2510,3241	.	3250,,3249	.	.	.	.	lung
7	55249089	55249089	G	A	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	.	ENSG00000146648:ENST00000455089:exon19:c.G2252A:p.G751D,ENSG00000146648:ENST00000275493:exon20:c.G2387A:p.G796D,ENSG00000146648:ENST00000454757:exon20:c.G2228A:p.G743D	EGFR:NM_005228:exon20:c.G2387A:p.G796D	clinvar: UNK 	 CancerVar: 12#Pathogenic EVS=[2, 0, 2, 1, 0, 0, 1, 0, 1, 2, 1, 2] 	.	.	.	.	6.753	32	0.0	5.92	0.983	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	EGFR:uc022ado.1:exon1:c.G92A:p.G31D,EGFR:uc010kzg.2:exon19:c.G2252A:p.G751D,EGFR:uc022adn.1:exon19:c.G2252A:p.G751D,EGFR:uc003tqk.3:exon20:c.G2387A:p.G796D,EGFR:uc011kco.2:exon20:c.G2228A:p.G743D,EGFR:uc022adm.1:exon20:c.G2387A:p.G796D	0.932	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	2712,,3240,3258,3247,3255,3246,3245,3234,3370,3214,3215,3216,3217,3236,3211,3212,3213,3251,3238,3239,3218,3219,3256,3257,3252,3235,2509,2508,2507,2506,3232,3233,3230,3261,3253,3263,3231,3265,3264,3267,3266,3269,3268,3244,3237,3248,3229,3228,3254,3260,3225,3224,3227,3226,3221,3220,3223,3222,3243,3262,3259,3242,2510,3241	.	3250,,3249	1.0	-2.59	0.871	3.295	lung
7	55249005	55249005	G	T	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs121913465	ENSG00000146648:ENST00000455089:exon19:c.G2168T:p.S723I,ENSG00000146648:ENST00000275493:exon20:c.G2303T:p.S768I,ENSG00000146648:ENST00000454757:exon20:c.G2144T:p.S715I	EGFR:NM_005228:exon20:c.G2303T:p.S768I	clinvar: Pathogenic 	 CancerVar: 13#Pathogenic EVS=[2, 0, 2, 1, 0, 0, 1, 1, 1, 2, 1, 2] 	.	.	.	.	6.143	28.4	0.002	5.85	0.992	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	EGFR:uc022ado.1:exon1:c.G8T:p.S3I,EGFR:uc010kzg.2:exon19:c.G2168T:p.S723I,EGFR:uc022adn.1:exon19:c.G2168T:p.S723I,EGFR:uc003tqk.3:exon20:c.G2303T:p.S768I,EGFR:uc011kco.2:exon20:c.G2144T:p.S715I,EGFR:uc022adm.1:exon20:c.G2303T:p.S768I	0.454	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	2712,,3258,3259,3251,3252,3253,3254,3255,3256,3257,3248,3243,3242,3241,3240,3247,3246,3245,3244,3370,3214,3453,3216,3261,3260,3263,3217,3265,3264,3267,3266,3269,3268,3457,3212,3461,3460,3455,3262,3452,3215,3450,3451,3456,3211,3454,3213,3458,3459,3218,3219,3462,3449,3448,3445,3444,3447,3446,3441,3440,3443,3442,2510,3232,3439,3230,3231,3236,3237,3234,3235,3238,3239,3434,3435,3436,3437,2509,2508,2507,2506,3438,3233,3229,3228,3225,3224,3227,3226,3221,3220,3223,3222	.	3250,,3249	1.0	-1.7	0.698	1.995	lung
7	55249022	55249022	G	A	EGFR	exonic	nonsynonymous SNV	ENSG00000146648	rs567477136	ENSG00000146648:ENST00000455089:exon19:c.G2185A:p.V729M,ENSG00000146648:ENST00000275493:exon20:c.G2320A:p.V774M,ENSG00000146648:ENST00000454757:exon20:c.G2161A:p.V721M	EGFR:NM_005228:exon20:c.G2320A:p.V774M	clinvar: UNK 	 CancerVar: 13#Pathogenic EVS=[2, 0, 2, 1, 0, 0, 1, 0, 2, 2, 1, 2] 	.	.	.	.	6.542	31	0.001	4.97	0.973	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	EGFR:uc022ado.1:exon1:c.G25A:p.V9M,EGFR:uc010kzg.2:exon19:c.G2185A:p.V729M,EGFR:uc022adn.1:exon19:c.G2185A:p.V729M,EGFR:uc003tqk.3:exon20:c.G2320A:p.V774M,EGFR:uc011kco.2:exon20:c.G2161A:p.V721M,EGFR:uc022adm.1:exon20:c.G2320A:p.V774M	0.503	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131550	211980;616069;	294023;	294023|-|<1 / 1 000 000|Autosomal recessive|Infancy<br>Neonatal|614328 616069 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04072 Phospholipase D signaling pathway~ko04144 Endocytosis~ko04151 PI3K-Akt signaling pathway~ko04214 Apoptosis - fly~ko04320 Dorso-ventral axis formation~ko04510 Focal adhesion~ko04520 Adherens junction~ko04540 Gap junction~ko04630 JAK-STAT signaling pathway~ko04810 Regulation of actin cytoskeleton~ko04912 GnRH signaling pathway~ko04915 Estrogen signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05160 Hepatitis C~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	2712,,3240,3258,3247,3255,3246,3245,3234,3370,3214,3215,3216,3217,3236,3211,3212,3213,3251,3238,3239,3218,3219,3256,3257,3252,3235,2509,2508,2507,2506,3232,3583,3584,3585,3586,3233,3230,3261,3253,3263,3231,3265,3264,3267,3266,3269,3268,3244,3587,3237,3248,3229,3228,3254,3260,3225,3224,3227,3226,3221,3220,3223,3222,3243,3262,3259,3242,2510,3241	.	3250,,3249	1.0	-0.3	0.617	3.86	lung
17	37880984	37880984	-	ATACGTGATGGC	ERBB2	exonic	nonframeshift insertion	ENSG00000141736	.	ENSG00000141736:ENST00000445658:exon14:c.1485_1486insATACGTGATGGC:p.A495delinsAIRDG,ENSG00000141736:ENST00000269571:exon20:c.2313_2314insATACGTGATGGC:p.A771delinsAIRDG,ENSG00000141736:ENST00000540147:exon20:c.2223_2224insATACGTGATGGC:p.A741delinsAIRDG,ENSG00000141736:ENST00000541774:exon20:c.2268_2269insATACGTGATGGC:p.A756delinsAIRDG,ENSG00000141736:ENST00000584450:exon20:c.2313_2314insATACGTGATGGC:p.A771delinsAIRDG,ENSG00000141736:ENST00000406381:exon22:c.2223_2224insATACGTGATGGC:p.A741delinsAIRDG,ENSG00000141736:ENST00000584601:exon24:c.2223_2224insATACGTGATGGC:p.A741delinsAIRDG	ERBB2:NM_001289937:exon20:c.2313_2314insATACGTGATGGC:p.A771delinsAIRDG,ERBB2:NM_004448:exon20:c.2313_2314insATACGTGATGGC:p.A771delinsAIRDG,ERBB2:NM_001005862:exon23:c.2223_2224insATACGTGATGGC:p.A741delinsAIRDG,ERBB2:NM_001289936:exon24:c.2268_2269insATACGTGATGGC:p.A756delinsAIRDG	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[2, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	ERBB2:uc010wek.2:exon14:c.1485_1486insATACGTGATGGC:p.A495delinsAIRDG,ERBB2:uc002hso.3:exon20:c.2313_2314insATACGTGATGGC:p.A771delinsAIRDG,ERBB2:uc002hsp.3:exon20:c.1722_1723insATACGTGATGGC:p.A574delinsAIRDG,ERBB2:uc010cwb.3:exon20:c.2313_2314insATACGTGATGGC:p.A771delinsAIRDG,ERBB2:uc002hsm.3:exon23:c.2223_2224insATACGTGATGGC:p.A741delinsAIRDG,ERBB2:uc010cwa.3:exon24:c.2268_2269insATACGTGATGGC:p.A756delinsAIRDG	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164870	137800;211980;613659;	182067;251627;251630;301;360;94;	182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~251627|-|-|Not applicable|All ages|137800 616568 ~251630|-|-|Not applicable|Adult|137800 616568 ~301|-|1-9 / 100 000|-|All ages|137800 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~94|Astrocytic tumor|1-9 / 100 000|-|All ages|137800 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04510 Focal adhesion~ko04520 Adherens junction~ko04530 Tight junction~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05215 Prostate cancer~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~	,4479,4478,4471,4470,4473,4472,4475,4474,4477,4476,4389,4388,4383,4382,4381,4380,4387,4386,4385,4384,4182,4408,4409,4404,4405,4406,4407,4400,4401,4402,4403,4484,4485,4486,4487,4480,4481,4482,4483,4488,4489,4419,4418,4417,4416,4415,4414,4413,4412,4411,4410,4497,4496,4495,4494,4493,4492,4491,4490,4499,4498,4428,4429,4422,4423,4420,4421,4426,4427,4424,4425,4503,4181,4180,4183,4502,4435,4434,4437,4436,4431,4430,4433,4432,4439,4438,4509,4440,4441,4442,4443,4444,4445,4446,4447,4448,4449,4377,4175,4176,4177,4178,4179,4395,4453,4452,4451,4450,4457,4456,4455,4454,4459,4458,4512,4513,4510,4511,4504,4501,4500,4468,4469,4466,4467,4464,4465,4462,4463,4460,4461,4398,4399,4390,4391,4392,4393,4394,4378,4396,4397,4379	.	.	.	.	.	.	lung
17	37868208	37868208	C	T	ERBB2	exonic	nonsynonymous SNV	ENSG00000141736	.	ENSG00000141736:ENST00000445658:exon2:c.C101T:p.S34F,ENSG00000141736:ENST00000582648:exon3:c.C253T:p.P85S,ENSG00000141736:ENST00000269571:exon8:c.C929T:p.S310F,ENSG00000141736:ENST00000540042:exon8:c.C839T:p.S280F,ENSG00000141736:ENST00000540147:exon8:c.C839T:p.S280F,ENSG00000141736:ENST00000541774:exon8:c.C884T:p.S295F,ENSG00000141736:ENST00000584450:exon8:c.C929T:p.S310F,ENSG00000141736:ENST00000406381:exon10:c.C839T:p.S280F,ENSG00000141736:ENST00000578199:exon11:c.C839T:p.S280F,ENSG00000141736:ENST00000584601:exon12:c.C839T:p.S280F	ERBB2:NM_001289937:exon8:c.C929T:p.S310F,ERBB2:NM_004448:exon8:c.C929T:p.S310F,ERBB2:NM_001005862:exon11:c.C839T:p.S280F,ERBB2:NM_001289938:exon11:c.C839T:p.S280F,ERBB2:NM_001289936:exon12:c.C884T:p.S295F	clinvar: Likely_pathogenic 	 CancerVar: 9#Likely_pathogenic EVS=[1, 0, 0, 1, 0, 0, 1, 1, 2, 1, 1, 1] 	.	.	.	.	6.634	32	0.026	5.83	0.993	.	.	Furin-like cysteine-rich domain;Insulin-like growth factor binding protein, N-terminal	ERBB2:uc010wek.2:exon2:c.C101T:p.S34F,ERBB2:uc002hsn.1:exon8:c.C929T:p.S310F,ERBB2:uc002hso.3:exon8:c.C929T:p.S310F,ERBB2:uc002hsp.3:exon8:c.C338T:p.S113F,ERBB2:uc010cwb.3:exon8:c.C929T:p.S310F,ERBB2:uc002hsl.3:exon11:c.C839T:p.S280F,ERBB2:uc002hsm.3:exon11:c.C839T:p.S280F,ERBB2:uc010cwa.3:exon12:c.C884T:p.S295F	-0.180	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164870	137800;211980;613659;	182067;251627;251630;301;360;94;	182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~251627|-|-|Not applicable|All ages|137800 616568 ~251630|-|-|Not applicable|Adult|137800 616568 ~301|-|1-9 / 100 000|-|All ages|137800 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~94|Astrocytic tumor|1-9 / 100 000|-|All ages|137800 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04020 Calcium signaling pathway~ko04066 HIF-1 signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04510 Focal adhesion~ko04520 Adherens junction~ko04530 Tight junction~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05215 Prostate cancer~ko05219 Bladder cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~	,4479,4478,4572,4573,4574,4575,4576,4577,4471,4470,4473,4472,4475,4474,4477,4476,4389,4388,4383,4382,4381,4380,4387,4386,4385,4384,4563,4562,4561,4560,4567,4566,4565,4564,4569,4568,4570,4408,4409,4571,4404,4405,4406,4407,4400,4401,4402,4403,4484,4485,4486,4487,4480,4481,4482,4483,4488,4489,4558,4559,4556,4557,4554,4555,4419,4418,4417,4416,4415,4414,4413,4412,4411,4410,4497,4496,4495,4494,4493,4492,4491,4490,4499,4498,4428,4429,4422,4423,4420,4421,4426,4427,4424,4425,4503,4502,4435,4434,4437,4436,4431,4430,4433,4432,4439,4438,4509,4440,4441,4442,4443,4444,4445,4446,4447,4448,4449,4377,4395,4453,4452,4451,4450,4457,4456,4455,4454,4459,4458,4512,4513,4510,4511,4504,4501,4500,4468,4469,4466,4467,4464,4465,4462,4463,4460,4461,4398,4399,4390,4391,4392,4393,4394,4378,4396,4397,4379	.	.	1.0	-0.11	0.444	2.15	breasr
2	212288925	212288925	G	A	ERBB4	exonic	stopgain	ENSG00000178568	.	ENSG00000178568:ENST00000342788:exon23:c.C2821T:p.Q941X,ENSG00000178568:ENST00000402597:exon23:c.C2791T:p.Q931X,ENSG00000178568:ENST00000436443:exon23:c.C2821T:p.Q941X	ERBB4:NM_001042599:exon23:c.C2821T:p.Q941X,ERBB4:NM_005235:exon23:c.C2821T:p.Q941X	clinvar: UNK 	 CancerVar: 6#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 1, 0, 1, 1] 	.	.	.	.	14.685	47	.	6.16	0.998	.	.	Protein kinase domain;Protein kinase-like domain;Serine-threonine/tyrosine-protein kinase catalytic domain;Tyrosine-protein kinase, catalytic domain	ERBB4:uc002veg.1:exon23:c.C2821T:p.Q941X,ERBB4:uc002veh.1:exon23:c.C2821T:p.Q941X,ERBB4:uc010zji.1:exon23:c.C2791T:p.Q931X,ERBB4:uc010zjj.1:exon23:c.C2791T:p.Q931X	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	600543	615515;	803;	803|ALS<br>Charcot disease<br>Lou Gehrig disease|1-9 / 100 000|Autosomal dominant<br>or&nbsp;Autosomal recessive<br>or&nbsp;Not applicable|Adult|105400 205250 300857 606070 606640 608030 608031 608627 611895 612069 612577 613435 613954 614696 614808 615426 615515 616208 616437 ~	~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04020 Calcium signaling pathway~ko04151 PI3K-Akt signaling pathway~ko05205 Proteoglycans in cancer~	,4763,4764	.	.	.	.	.	.	skin
4	153250867	153250867	G	A	FBXW7	exonic	nonsynonymous SNV	ENSG00000109670	.	ENSG00000109670:ENST00000393956:exon6:c.C665T:p.S222F,ENSG00000109670:ENST00000263981:exon7:c.C953T:p.S318F,ENSG00000109670:ENST00000296555:exon7:c.C839T:p.S280F,ENSG00000109670:ENST00000603841:exon7:c.C1193T:p.S398F,ENSG00000109670:ENST00000281708:exon8:c.C1193T:p.S398F,ENSG00000109670:ENST00000603548:exon9:c.C1193T:p.S398F	FBXW7:NM_001013415:exon7:c.C839T:p.S280F,FBXW7:NM_018315:exon7:c.C953T:p.S318F,FBXW7:NM_033632:exon8:c.C1193T:p.S398F	clinvar: UNK 	 CancerVar: 7#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 2, 1, 1] 	.	.	.	.	6.421	29.7	0.032	5.99	1.000	.	.	F-box domain;WD40-repeat-containing domain;WD40/YVTN repeat-like-containing domain	FBXW7:uc011cih.2:exon6:c.C665T:p.S222F,FBXW7:uc003imq.3:exon7:c.C953T:p.S318F,FBXW7:uc003imr.3:exon7:c.C839T:p.S280F,FBXW7:uc003ims.3:exon8:c.C1193T:p.S398F,FBXW7:uc003imt.3:exon8:c.C1193T:p.S398F,FBXW7:uc011cii.2:exon9:c.C1193T:p.S398F	0.621	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	606278	.	.	.	.	,4944,4941,4940,4943,4942,4928	.	.	1.0	-0.85	0.729	3.785	lung
10	8115876	8115876	-	T	GATA3	exonic	frameshift insertion	ENSG00000107485	.	ENSG00000107485:ENST00000346208:exon6:c.1222_1223insT:p.P408fs,ENSG00000107485:ENST00000379328:exon6:c.1225_1226insT:p.P409fs	GATA3:NM_001002295:exon6:c.1225_1226insT:p.P409fs,GATA3:NM_002051:exon6:c.1222_1223insT:p.P408fs	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	GATA3:uc001ijz.3:exon6:c.1225_1226insT:p.P409fs,GATA3:uc001ika.3:exon6:c.1222_1223insT:p.P408fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	131320	146255;	2237;	2237|Barakat syndrome<br>HDR syndrome|<1 / 1 000 000|Autosomal dominant|Childhood|146255 ~	.	,5846,5845	.	.	.	.	.	.	breast
20	57480477	57480477	G	A	GNAS	exonic	nonsynonymous SNV	ENSG00000087460	.	ENSG00000087460:ENST00000265620:exon5:c.G427A:p.G143R,ENSG00000087460:ENST00000371095:exon5:c.G430A:p.G144R,ENSG00000087460:ENST00000371102:exon5:c.G2359A:p.G787R,ENSG00000087460:ENST00000306090:exon6:c.G430A:p.G144R,ENSG00000087460:ENST00000349036:exon6:c.G523A:p.G175R,ENSG00000087460:ENST00000354359:exon6:c.G475A:p.G159R,ENSG00000087460:ENST00000371085:exon6:c.G472A:p.G158R,ENSG00000087460:ENST00000371100:exon6:c.G2401A:p.G801R,ENSG00000087460:ENST00000603546:exon6:c.G295A:p.G99R,ENSG00000087460:ENST00000604005:exon6:c.G295A:p.G99R	GNAS:NM_001077489:exon5:c.G427A:p.G143R,GNAS:NM_080426:exon5:c.G430A:p.G144R,GNAS:NM_000516:exon6:c.G472A:p.G158R,GNAS:NM_001077488:exon6:c.G475A:p.G159R,GNAS:NM_001309840:exon6:c.G295A:p.G99R,GNAS:NM_001309861:exon6:c.G295A:p.G99R,GNAS:NM_080425:exon6:c.G2401A:p.G801R	clinvar: UNK 	 CancerVar: 7#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 2, 1, 1] 	.	.	.	.	6.638	32	0.0	5.93	0.995	.	.	G protein alpha subunit, helical insertion	GNAS:uc002yae.3:exon3:c.G247A:p.G83R,GNAS:uc002yad.3:exon4:c.G145A:p.G49R,GNAS:uc002yaa.3:exon5:c.G427A:p.G143R,GNAS:uc021wfp.1:exon5:c.G430A:p.G144R,GNAS:uc002xzt.3:exon6:c.G376A:p.G126R,GNAS:uc002xzw.3:exon6:c.G2401A:p.G801R,GNAS:uc002xzx.3:exon6:c.G295A:p.G99R,GNAS:uc010gjq.3:exon6:c.G295A:p.G99R,GNAS:uc021wfn.1:exon6:c.G472A:p.G158R,GNAS:uc021wfo.1:exon6:c.G475A:p.G159R	0.500	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	139320	102200;103580;166350;174800;219080;603233;612462;612463;	79445;79444;94089;189427;562;2762;79443;314777;96256;963;99725;	79445|AHO-PPHP syndrome<br>Albright hereditary osteodystrophy-PPHP syndrome|Unknown|Autosomal dominant|All ages|612463 ~79444|-|Unknown|Autosomal dominant|Infancy<br>Neonatal<br>Childhood|612462 ~94089|-|Unknown|Autosomal dominant<br>or&nbsp;Not applicable|Neonatal<br>Infancy<br>Childhood<br>Adolescent|603233 ~189427|Primary bilateral macronodular adrenal hyperplasia|<1 / 1 000 000|Autosomal dominant<br>or&nbsp;Not applicable|All ages|219080 615954 ~562|Gonadotropin-independent female-limited sexual precocity|1-9 / 1 000 000|Not applicable|Childhood|174800 ~2762|Familial ectopic ossification<br>POH|-|Autosomal dominant|Infancy<br>Childhood<br>Adolescent<br>Adult|166350 ~79443|AHO-PHP syndrome Ia<br>Albright hereditary osteodystrophy-PHP syndrome Ia|Unknown|Autosomal dominant|Infancy<br>Neonatal<br>Childhood|103580 ~314777|FIPA|Unknown|Autosomal dominant|All ages|102200 600634 ~96256|Somatotropinoma|-|-|-|102200 ~963|-|1-9 / 100 000|Not applicable|Adult|102200 300943 ~99725|Hypophyseal gigantism<br>Infantile and juvenile forms of acromegaly|-|-|-|102200 ~	~ko01522 Endocrine resistance~ko04015 Rap1 signaling pathway~ko04020 Calcium signaling pathway~ko04024 cAMP signaling pathway~ko04072 Phospholipase D signaling pathway~ko04261 Adrenergic signaling in cardiomyocytes~ko04270 Vascular smooth muscle contraction~ko04361 Axon regeneration~ko04540 Gap junction~ko04611 Platelet activation~ko04713 Circadian entrainment~ko04714 Thermogenesis~ko04724 Glutamatergic synapse~ko04726 Serotonergic synapse~ko04728 Dopaminergic synapse~ko04730 Long-term depression~ko04750 Inflammatory mediator regulation of TRP channels~ko04911 Insulin secretion~ko04912 GnRH signaling pathway~ko04913 Ovarian steroidogenesis~ko04915 Estrogen signaling pathway~ko04916 Melanogenesis~ko04918 Thyroid hormone synthesis~ko04921 Oxytocin signaling pathway~ko04922 Glucagon signaling pathway~ko04923 Regulation of lipolysis in adipocytes~ko04924 Renin secretion~ko04925 Aldosterone synthesis and secretion~ko04926 Relaxin signaling pathway~ko04927 Cortisol synthesis and secretion~ko04928 Parathyroid hormone synthesis, secretion and action~ko04934 Cushing syndrome~ko04961 Endocrine and other factor-regulated calcium reabsorption~ko04962 Vasopressin-regulated water reabsorption~ko04970 Salivary secretion~ko04971 Gastric acid secretion~ko04972 Pancreatic secretion~ko04976 Bile secretion~ko05030 Cocaine addiction~ko05031 Amphetamine addiction~ko05032 Morphine addiction~ko05034 Alcoholism~ko05110 Vibrio cholerae infection~ko05142 Chagas disease (American trypanosomiasis)~ko05146 Amoebiasis~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05200 Pathways in cancer~ko05414 Dilated cardiomyopathy (DCM)~	,5904,5905	.	.	0.998	-2.54	0.642	3.805	lung
2	209113113	209113113	G	A	IDH1	exonic	nonsynonymous SNV	ENSG00000138413	rs121913499	ENSG00000138413:ENST00000415282:exon3:c.C394T:p.R132C,ENSG00000138413:ENST00000345146:exon4:c.C394T:p.R132C,ENSG00000138413:ENST00000415913:exon4:c.C394T:p.R132C,ENSG00000138413:ENST00000446179:exon4:c.C394T:p.R132C	IDH1:NM_001282386:exon4:c.C394T:p.R132C,IDH1:NM_001282387:exon4:c.C394T:p.R132C,IDH1:NM_005896:exon4:c.C394T:p.R132C	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 12#Pathogenic EVS=[1, 1, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	7.432	34	0.025	5.57	0.998	.	.	Isopropylmalate dehydrogenase-like domain	IDH1:uc002vcs.3:exon4:c.C394T:p.R132C,IDH1:uc002vct.3:exon4:c.C394T:p.R132C,IDH1:uc002vcu.3:exon4:c.C394T:p.R132C	0.732	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	147700	137800;	182067;251627;251630;301;360;94;	182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~251627|-|-|Not applicable|All ages|137800 616568 ~251630|-|-|Not applicable|Adult|137800 616568 ~301|-|1-9 / 100 000|-|All ages|137800 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~94|Astrocytic tumor|1-9 / 100 000|-|All ages|137800 ~	~ko00020 Citrate cycle (TCA cycle)~ko00480 Glutathione metabolism~ko00720 Carbon fixation pathways in prokaryotes~ko01100 Metabolic pathways~ko01110 Biosynthesis of secondary metabolites~ko01120 Microbial metabolism in diverse environments~ko01130 Biosynthesis of antibiotics~ko01200 Carbon metabolism~ko01210 2-Oxocarboxylic acid metabolism~ko01230 Biosynthesis of amino acids~ko04146 Peroxisome~~M00009 Citrate cycle (TCA cycle, Krebs cycle)~M00010 Citrate cycle, first carbon oxidation, oxaloacetate =>~~M00173 Reductive citrate cycle (Arnon-Buchanan cycle)~M00740 Methylaspartate cycle~	,6052,6056,6006,6007,6004,6005,6002,6003,6000,6001,6008,6009,6028,6029,6040,6041,6060,6047,6044,6045,6020,6021,6048,6049,6042,6062,6061,6055,6054,5999,6043,6057,6010,6012,6015,6014,6016,6063,6059,6058,6033,6032,6031,6030,6051,6050,6053,6034	,6013,6019,6018,6046,6023,6026	6011,,6017,6022,6024,6025,6027	0.259	-2.2	0.809	4.54	skin
4	55593588	55593608	ATGTATGAAGTACAGTGGAAG	-	KIT	exonic	nonframeshift deletion	ENSG00000157404	.	ENSG00000157404:ENST00000288135:exon11:c.1654_1674del:p.552_558del,ENSG00000157404:ENST00000412167:exon11:c.1642_1662del:p.548_554del	KIT:NM_000222:exon11:c.1654_1674del:p.552_558del,KIT:NM_001093772:exon11:c.1642_1662del:p.548_554del	clinvar: UNK 	 CancerVar: 8#Likely_pathogenic EVS=[2, 1, 0, 0, 0, 0, 1, 0, 1, 0, 1, 2] 	.	.	.	.	.	.	.	.	.	.	.	.	KIT:uc010igt.2:wholegene	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164920	154800;172800;273300;601626;606764;	44890;519;363483;363494;363504;842;876;99865;2884;79457;98292;	44890|GIST<br>Gastrointestinal stromal sarcoma|1-5 / 10 000|Not applicable<br>or&nbsp;Autosomal dominant|Childhood<br>Adolescent<br>Adult|606764 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~2884|-|Unknown|Autosomal dominant|Infancy<br>Neonatal|172800 ~79457|Urticaria pigmentosa|Unknown|Not applicable|All ages|154800 ~98292|-|1-9 / 100 000|-|All ages|154800 ~	~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04072 Phospholipase D signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04640 Hematopoietic cell lineage~ko04916 Melanogenesis~ko05200 Pathways in cancer~ko05221 Acute myeloid leukemia~ko05224 Breast cancer~ko05230 Central carbon metabolism in cancer~	6590,6591,6592,,6381,6380,6519,6478,6473,6472,6471,6470,6477,6476,6475,6474,6583,6582,6580,6587,6585,6584,6589,6588,6520,6611,6610,6633,6635,6634,6468,6469,6461,6462,6463,6464,6465,6466,6467,6379	,6586	.	.	.	.	.	Stomach
12	25378647	25378647	T	A	KRAS	exonic	nonsynonymous SNV	ENSG00000133703	.	ENSG00000133703:ENST00000256078:exon4:c.A351T:p.K117N,ENSG00000133703:ENST00000311936:exon4:c.A351T:p.K117N	KRAS:NM_004985:exon4:c.A351T:p.K117N,KRAS:NM_033360:exon4:c.A351T:p.K117N	clinvar: Pathogenic 	 CancerVar: 13#Pathogenic EVS=[2, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 2] 	.	.	.	.	5.706	26.8	0.012	0.583	1.000	.	.	P-loop containing nucleoside triphosphate hydrolase;Small GTP-binding protein domain	KRAS:uc001rgp.1:exon4:c.A351T:p.K117N,KRAS:uc001rgq.1:exon4:c.A351T:p.K117N	0.901	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	190070	109800;114480;137215;163200;211980;260350;601626;609942;614470;615278;	1340;268114;648;519;1333;2612;26106;227535;	1340|CFC syndrome|Unknown|Autosomal dominant|Antenatal<br>Neonatal|115150 615278 615279 615280 ~268114|ALPS type 4<br>ALPS type IV<br>Autoimmune lymphoproliferative syndrome type 4<br>Autoimmune lymphoproliferative syndrome type IV<br>RALD|<1 / 1 000 000|Unknown|Childhood<br>Infancy|614470 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~519|AML<br>Acute myelogenous leukemia|1-9 / 100 000|-|All ages|601626 ~1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~2612|Nevus sebaceus of Jadassohn<br>Nevus sebaceus syndrome<br>Organoid nevus syndrome<br>Schimmelpenning syndrome<br>Solomon syndrome|Unknown|Not applicable|Childhood|163200 ~26106|FDGC<br>Familial diffuse cancer of stomach<br>Familial diffuse gastric cancer<br>HDGC<br>Hereditary diffuse cancer of stomach<br>Hereditary diffuse gastric adenocarcinoma|Unknown|Autosomal dominant|Adult|137215 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko04010 MAPK signaling pathway~ko04012 ErbB signaling pathway~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04062 Chemokine signaling pathway~ko04068 FoxO signaling pathway~ko04071 Sphingolipid signaling pathway~ko04072 Phospholipase D signaling pathway~ko04113 Meiosis - yeast~ko04137 Mitophagy - animal~ko04138 Autophagy - yeast~ko04140 Autophagy - animal~ko04150 mTOR signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04213 Longevity regulating pathway - multiple species~ko04214 Apoptosis - fly~ko04218 Cellular senescence~ko04320 Dorso-ventral axis formation~ko04360 Axon guidance~ko04370 VEGF signaling pathway~ko04371 Apelin signaling pathway~ko04540 Gap junction~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04625 C-type lectin receptor signaling pathway~ko04650 Natural killer cell mediated cytotoxicity~ko04660 T cell receptor signaling pathway~ko04662 B cell receptor signaling pathway~ko04664 Fc epsilon RI signaling pathway~ko04714 Thermogenesis~ko04720 Long-term potentiation~ko04722 Neurotrophin signaling pathway~ko04725 Cholinergic synapse~ko04726 Serotonergic synapse~ko04730 Long-term depression~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04912 GnRH signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04915 Estrogen signaling pathway~ko04916 Melanogenesis~ko04917 Prolactin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko04921 Oxytocin signaling pathway~ko04926 Relaxin signaling pathway~ko04929 GnRH secretion~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko04960 Aldosterone-regulated sodium reabsorption~ko05034 Alcoholism~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05170 Human immunodeficiency virus 1 infection~ko05200 Pathways in cancer~ko05203 Viral carcinogenesis~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	,7054,7064,6837,6850,6835,7061,6813,6838,7037,7059,7030,6842,7032,7033,7034,7035,7018,6843,7016,7017,7014,7015,7012,7003,7010,6836,7058,7002,7045,7005,7038,7051,7056,7057,7047,7004,7019,7048,7007,7055,7006,6839,7031,6998,6999,7044,7039,6997,7049,7009,7008,6848,6849,7027,7040,7025,7024,7001,7000,6840,6841,6846,6847,6844,6845,7023,7013,7043,7022,7062,7063,7021,7036,7060,7052,7028,7046,7053,7029,7041,7042,7050	.	,7020,7026,7011	1.0	-2.31	0.948	5	Colorectal
7	116412041	116412041	A	G	MET	exonic	nonsynonymous SNV	ENSG00000105976	.	ENSG00000105976:ENST00000318493:exon14:c.A3080G:p.E1027G,ENSG00000105976:ENST00000397752:exon14:c.A3026G:p.E1009G	MET:NM_000245:exon14:c.A3026G:p.E1009G,MET:NM_001127500:exon14:c.A3080G:p.E1027G	clinvar: UNK 	 CancerVar: 6#Uncertain_significance EVS=[2, 0, 0, 1, 0, 0, 1, 0, 0, -1, 1, 2] 	.	.	.	.	6.225	28.8	0.005	5.67	1.000	0.5413	0.458	.	MET:uc003vij.3:exon14:c.A3026G:p.E1009G,MET:uc010lkh.3:exon14:c.A3080G:p.E1027G,MET:uc011knj.2:exon14:c.A1736G:p.E579G	-0.106	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	164860	114550;605074;607278;616705;	90636;47044;449;88673;	90636|Autosomal recessive isolated neurosensory deafness type DFNB<br>Autosomal recessive isolated sensorineural deafness type DFNB<br>Autosomal recessive non-syndromic neurosensory deafness type DFNB|Unknown|Autosomal recessive|Infancy<br>Neonatal|220290 600060 600316 600791 600792 600971 600974 601071 601072 601386 601869 602092 603010 603098 603629 603678 603720 604060 605428 605818 607039 607084 607101 607239 607821 608219 608264 608265 608565 608653 609006 609439 609533 609646 609647 609706 609823 609941 609946 609952 610143 610153 610154 610212 610220 610248 610265 610419 611022 611451 612433 612645 612789 613079 613285 613307 613391 613392 613453 613685 613718 613865 613916 614035 614414 614617 614861 614899 614934 614944 614945 615429 615540 615837 615974 616042 616515 616705 616958 ~47044|HPRCC|-|Autosomal dominant|Adult|605074 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~	~ko01521 EGFR tyrosine kinase inhibitor resistance~ko04010 MAPK signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04360 Axon guidance~ko04361 Axon regeneration~ko04510 Focal adhesion~ko04520 Adherens junction~ko05100 Bacterial invasion of epithelial cells~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05144 Malaria~ko05200 Pathways in cancer~ko05202 Transcriptional misregulation in cancer~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05211 Renal cell carcinoma~ko05218 Melanoma~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~	,7498,7499,7492,7493,7490,7491,7496,7497,7495,7485,7487,7486,7489,7488,7441,7440,7443,7442,7445,7444,7447,7446,7504,7500,7501,7502,7503	.	.	0.999	-0.81	0.402	0.345	lung
1	45797228	45797228	C	T	MUTYH	exonic	nonsynonymous SNV	ENSG00000132781	rs36053993	ENSG00000132781:ENST00000488731:exon4:c.G188A:p.G63D,ENSG00000132781:ENST00000528332:exon4:c.G230A:p.G77D,ENSG00000132781:ENST00000529984:exon4:c.G188A:p.G63D,ENSG00000132781:ENST00000467459:exon5:c.G520A:p.V174I,ENSG00000132781:ENST00000354383:exon13:c.G1106A:p.G369D,ENSG00000132781:ENST00000355498:exon13:c.G1103A:p.G368D,ENSG00000132781:ENST00000372098:exon13:c.G1178A:p.G393D,ENSG00000132781:ENST00000372100:exon13:c.G1136A:p.G379D,ENSG00000132781:ENST00000372110:exon13:c.G1148A:p.G383D,ENSG00000132781:ENST00000372115:exon13:c.G1145A:p.G382D,ENSG00000132781:ENST00000448481:exon13:c.G1136A:p.G379D,ENSG00000132781:ENST00000450313:exon13:c.G1187A:p.G396D,ENSG00000132781:ENST00000456914:exon13:c.G1103A:p.G368D,ENSG00000132781:ENST00000528013:exon13:c.G1145A:p.G382D,ENSG00000132781:ENST00000372104:exon14:c.G1103A:p.G368D	MUTYH:NM_001048171:exon13:c.G1145A:p.G382D,MUTYH:NM_001048172:exon13:c.G1106A:p.G369D,MUTYH:NM_001048173:exon13:c.G1103A:p.G368D,MUTYH:NM_001048174:exon13:c.G1103A:p.G368D,MUTYH:NM_001128425:exon13:c.G1187A:p.G396D,MUTYH:NM_001293190:exon13:c.G1148A:p.G383D,MUTYH:NM_001293191:exon13:c.G1136A:p.G379D,MUTYH:NM_001293192:exon13:c.G827A:p.G276D,MUTYH:NM_001293196:exon13:c.G827A:p.G276D,MUTYH:NM_012222:exon13:c.G1178A:p.G393D,MUTYH:NM_001293195:exon14:c.G1103A:p.G368D	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 5#Uncertain_significance EVS=[0, 0, 0, 1, 0, 0, 0, 1, 0, 2, 1, 0] 	0.0028	0.0038	0.00239617	0.0032	6.350	29.4	0.0	5.4	0.980	0.9948	0.792	MutY, C-terminal;NUDIX hydrolase domain;NUDIX hydrolase domain-like	MUTYH:uc010oll.2:exon4:c.G230A:p.G77D,MUTYH:uc001cnf.3:exon13:c.G1103A:p.G368D,MUTYH:uc001cng.3:exon13:c.G1136A:p.G379D,MUTYH:uc001cnh.3:exon13:c.G1106A:p.G369D,MUTYH:uc001cni.3:exon13:c.G1103A:p.G368D,MUTYH:uc001cnj.3:exon13:c.G827A:p.G276D,MUTYH:uc001cnl.3:exon13:c.G1145A:p.G382D,MUTYH:uc001cnm.3:exon13:c.G1178A:p.G393D,MUTYH:uc001cnn.3:exon13:c.G1148A:p.G383D,MUTYH:uc001cno.3:exon13:c.G827A:p.G276D,MUTYH:uc009vxp.3:exon13:c.G1187A:p.G396D,MUTYH:uc009vxo.3:exon14:c.G1103A:p.G368D	0.148	AFR:0.0015,AMR:0.0036,EAS:0.0006,FIN:0.0023,NFE:0.0047,OTH:0.0031,ASJ:0	604933	132600;608456;613659;	220460;247798;91414;	220460|AFAP<br>Attenuated FAP<br>Attenuated familial polyposis coli|-|Autosomal dominant<br>or&nbsp;Autosomal recessive|Adult|175100 608456 612591 615083 616415 ~247798|MUTYH-related AFAP<br>MUTYH-related attenuated FAP<br>MUTYH-related attenuated familial polyposis coli|-|Autosomal dominant<br>or&nbsp;Autosomal recessive|-|608456 ~91414|Epithelioma calcificans of Malherbe<br>Pilomatricoma|Unknown|Not applicable|Childhood<br>Adolescent<br>Adult|132600 ~	.	.	.	.	1.0	-3.78	0.540	3.745	prostate
22	30032748	30032748	G	A	NF2	exonic	stopgain	ENSG00000186575	.	ENSG00000186575:ENST00000338641:exon2:c.G123A:p.W41X,ENSG00000186575:ENST00000361166:exon2:c.G123A:p.W41X,ENSG00000186575:ENST00000361452:exon2:c.G123A:p.W41X,ENSG00000186575:ENST00000397789:exon2:c.G123A:p.W41X,ENSG00000186575:ENST00000403435:exon2:c.G123A:p.W41X,ENSG00000186575:ENST00000403999:exon2:c.G123A:p.W41X,ENSG00000186575:ENST00000413209:exon2:c.G123A:p.W41X	NF2:NM_000268:exon2:c.G123A:p.W41X,NF2:NM_016418:exon2:c.G123A:p.W41X,NF2:NM_181825:exon2:c.G123A:p.W41X,NF2:NM_181829:exon2:c.G123A:p.W41X,NF2:NM_181832:exon2:c.G123A:p.W41X,NF2:NM_181833:exon2:c.G123A:p.W41X	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	12.809	40	.	6.02	1.000	.	.	Band 4.1 domain;FERM domain;FERM, N-terminal;Ubiquitin-related domain	NF2:uc003afy.4:exon2:c.G123A:p.W41X,NF2:uc003age.4:exon2:c.G123A:p.W41X,NF2:uc003agf.4:exon2:c.G123A:p.W41X,NF2:uc003agg.4:exon2:c.G123A:p.W41X,NF2:uc003agh.4:exon2:c.G123A:p.W41X,NF2:uc003agj.4:exon2:c.G123A:p.W41X,NF2:uc003agc.4:exon3:c.G9A:p.W3X	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	607379	101000;162091;607174;	263662;93921;637;	263662|-|Unknown|Autosomal dominant|All ages|607174 ~93921|NF3<br>Neurilemmomatosis<br>Schwannomatosis|Unknown|Autosomal dominant|Adult<br>Elderly|162091 162260 615670 ~637|Bilateral acoustic neurofibromatosis<br>Central neurofibromatosis<br>NF2|1-9 / 100 000|Autosomal dominant|All ages|101000 ~	.	,7770,7764,7765,7766,7767,7760,7758,7762,7763,7755,7759,7757,7756,7768,7769,7761	.	.	.	.	.	.	kidney 
2	178098962	178098962	A	G	NFE2L2	exonic	nonsynonymous SNV	ENSG00000116044	.	ENSG00000116044:ENST00000397062:exon2:c.T83C:p.I28T,ENSG00000116044:ENST00000397063:exon2:c.T35C:p.I12T,ENSG00000116044:ENST00000421929:exon2:c.T35C:p.I12T,ENSG00000116044:ENST00000423513:exon2:c.T35C:p.I12T,ENSG00000116044:ENST00000446151:exon2:c.T35C:p.I12T,ENSG00000116044:ENST00000448782:exon2:c.T35C:p.I12T,ENSG00000116044:ENST00000449627:exon2:c.T35C:p.I12T,ENSG00000116044:ENST00000586532:exon3:c.T80C:p.I27T,ENSG00000116044:ENST00000588123:exon3:c.T35C:p.I12T,ENSG00000116044:ENST00000464747:exon5:c.T35C:p.I12T	NFE2L2:NM_001145412:exon2:c.T35C:p.I12T,NFE2L2:NM_001145413:exon2:c.T35C:p.I12T,NFE2L2:NM_001313900:exon2:c.T35C:p.I12T,NFE2L2:NM_001313901:exon2:c.T35C:p.I12T,NFE2L2:NM_001313902:exon2:c.T83C:p.I28T,NFE2L2:NM_001313903:exon2:c.T83C:p.I28T,NFE2L2:NM_006164:exon2:c.T83C:p.I28T	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[0, 0, 0, 0, 0, 0, 1, 0, 2, 1, 1, 0] 	.	.	.	.	5.978	27.8	0.001	5.78	0.998	.	.	.	NFE2L2:uc002ulg.5:exon2:c.T35C:p.I12T,NFE2L2:uc002ulh.5:exon2:c.T83C:p.I28T,NFE2L2:uc010fra.3:exon2:c.T35C:p.I12T,NFE2L2:uc010frb.3:exon2:c.T35C:p.I12T,NFE2L2:uc010zfa.3:exon2:c.T35C:p.I12T,NFE2L2:uc002uli.5:exon5:c.T35C:p.I12T	-0.519	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	600492	.	.	.	~ko04141 Protein processing in endoplasmic reticulum~ko04212 Longevity regulating pathway - worm~ko05200 Pathways in cancer~ko05225 Hepatocellular carcinoma~ko05418 Fluid shear stress and atherosclerosis~	.	.	.	0.999	1.49	0.239	2.835	lung
3	178936082	178936082	G	A	PIK3CA	exonic	nonsynonymous SNV	ENSG00000121879	rs121913273	ENSG00000121879:ENST00000263967:exon10:c.G1624A:p.E542K	PIK3CA:NM_006218:exon10:c.G1624A:p.E542K	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 8#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, -1, 1, 1] 	.	.	.	.	5.844	27.3	0.016	5.78	0.997	.	.	Armadillo-type fold;Phosphoinositide 3-kinase, accessory (PIK) domain	PIK3CA:uc003fjk.3:exon10:c.G1624A:p.E542K	-0.729	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	171834	114480;114500;114550;162900;167000;182000;211980;602501;612918;613659;615108;	201;140944;60040;79414;449;88673;227535;	201|Cowden disease<br>Multiple hamartoma syndrome|1-9 / 1 000 000|Autosomal dominant|All ages|158350 612359 615106 615107 615108 615109 616858 ~140944|Congenital lipomatous overgrowth-vascular malformation-epidermal nevi-skeletal anomaly syndrome<br>Congenital lipomatous overgrowth-vascular malformation-epidermal nevi-spinal anomaly syndrome|<1 / 1 000 000|Not applicable|Infancy<br>Neonatal|612918 ~60040|MCAP<br>MCM<br>MCMTC<br>Macrocephaly-capillary malformation syndrome<br>Macrocephaly-cutis marmorata telangiectatica congenita syndrome<br>Megalencephaly-capillary malformation syndrome<br>Megalencephaly-cutis marmorata telangiectatica congenita syndrome|<1 / 1 000 000|Not applicable|Infancy<br>Neonatal|602501 ~79414|Wooly hair nevus|-|Not applicable|Neonatal<br>Infancy|162900 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko00562 Inositol phosphate metabolism~ko01100 Metabolic pathways~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04012 ErbB signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04070 Phosphatidylinositol signaling system~ko04071 Sphingolipid signaling pathway~ko04072 Phospholipase D signaling pathway~ko04140 Autophagy - animal~ko04150 mTOR signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04152 AMPK signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04212 Longevity regulating pathway - worm~ko04213 Longevity regulating pathway - multiple species~ko04218 Cellular senescence~ko04360 Axon guidance~ko04361 Axon regeneration~ko04370 VEGF signaling pathway~ko04380 Osteoclast differentiation~ko04510 Focal adhesion~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04611 Platelet activation~ko04620 Toll-like receptor signaling pathway~ko04625 C-type lectin receptor signaling pathway~ko04630 JAK-STAT signaling pathway~ko04650 Natural killer cell mediated cytotoxicity~ko04660 T cell receptor signaling pathway~ko04662 B cell receptor signaling pathway~ko04664 Fc epsilon RI signaling pathway~ko04666 Fc gamma R-mediated phagocytosis~ko04668 TNF signaling pathway~ko04670 Leukocyte transendothelial migration~ko04722 Neurotrophin signaling pathway~ko04725 Cholinergic synapse~ko04750 Inflammatory mediator regulation of TRP channels~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04915 Estrogen signaling pathway~ko04917 Prolactin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko04923 Regulation of lipolysis in adipocytes~ko04926 Relaxin signaling pathway~ko04929 GnRH secretion~ko04930 Type II diabetes mellitus~ko04931 Insulin resistance~ko04932 Non-alcoholic fatty liver disease (NAFLD)~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko04960 Aldosterone-regulated sodium reabsorption~ko04973 Carbohydrate digestion and absorption~ko05100 Bacterial invasion of epithelial cells~ko05135 Yersinia infection~ko05142 Chagas disease (American trypanosomiasis)~ko05146 Amoebiasis~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05162 Measles~ko05163 Human cytomegalovirus infection~ko05164 Influenza A~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05169 Epstein-Barr virus infection~ko05170 Human immunodeficiency virus 1 infection~ko05200 Pathways in cancer~ko05203 Viral carcinogenesis~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05222 Small cell lung cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~ko05418 Fluid shear stress and atherosclerosis~	,8985,8984,8987,8986,8981,8980,8983,8982,8989,8988,8673,8672,8671,8659,8658,8670,8909,8908,8651,8650,8652,8676,8686,8675,8674,8978,8979,8970,8971,8972,8973,8974,8975,8976,8977,9014,9015,8680,8681,9010,9011,9012,9013,8688,8677,8660,8661,8662,8969,8968,8963,8962,8961,8960,8967,8966,8965,8964,8666,8667,9007,9006,9005,9004,9003,9002,9001,9000,8690,9009,9008,8956,8957,8954,8955,8952,8953,8950,8951,8663,8958,8959,8664,9032,9033,9030,9031,9034,9035,8941,8940,8943,8942,8945,8944,8947,8946,8949,8948,8911,8770,8999,9029,9028,9025,9027,9026,8682,8683,8934,8935,8936,8937,8930,8931,8932,8933,8668,8669,8938,8939,8687,8684,8685,8995,8689,8910,8927,8926,8925,8924,8923,8922,8921,8920,8929,8928,8915,8665,8644,8998,8645,8992,8990,8991,8996,8997,8994,8643,8912,8913,8767,8766,8916,8917,8914,8649,8918,8919,8769,8768	.	,8993,8679,8678	0.995	0.05	0.309	1.27	lung
3	178936095	178936095	A	C	PIK3CA	exonic	nonsynonymous SNV	ENSG00000121879	.	ENSG00000121879:ENST00000263967:exon10:c.A1637C:p.Q546P	PIK3CA:NM_006218:exon10:c.A1637C:p.Q546P	clinvar: Pathogenic/Likely_pathogenic 	 CancerVar: 8#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 1, 2, -1, 1, 1] 	.	.	.	.	4.375	24.1	0.067	5.78	0.998	.	.	Armadillo-type fold;Phosphoinositide 3-kinase, accessory (PIK) domain	PIK3CA:uc003fjk.3:exon10:c.A1637C:p.Q546P	-0.211	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	171834	114480;114500;114550;162900;167000;182000;211980;602501;612918;613659;615108;	201;140944;60040;79414;449;88673;227535;	201|Cowden disease<br>Multiple hamartoma syndrome|1-9 / 1 000 000|Autosomal dominant|All ages|158350 612359 615106 615107 615108 615109 616858 ~140944|Congenital lipomatous overgrowth-vascular malformation-epidermal nevi-skeletal anomaly syndrome<br>Congenital lipomatous overgrowth-vascular malformation-epidermal nevi-spinal anomaly syndrome|<1 / 1 000 000|Not applicable|Infancy<br>Neonatal|612918 ~60040|MCAP<br>MCM<br>MCMTC<br>Macrocephaly-capillary malformation syndrome<br>Macrocephaly-cutis marmorata telangiectatica congenita syndrome<br>Megalencephaly-capillary malformation syndrome<br>Megalencephaly-cutis marmorata telangiectatica congenita syndrome|<1 / 1 000 000|Not applicable|Infancy<br>Neonatal|602501 ~79414|Wooly hair nevus|-|Not applicable|Neonatal<br>Infancy|162900 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko00562 Inositol phosphate metabolism~ko01100 Metabolic pathways~ko01521 EGFR tyrosine kinase inhibitor resistance~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04012 ErbB signaling pathway~ko04014 Ras signaling pathway~ko04015 Rap1 signaling pathway~ko04024 cAMP signaling pathway~ko04062 Chemokine signaling pathway~ko04066 HIF-1 signaling pathway~ko04068 FoxO signaling pathway~ko04070 Phosphatidylinositol signaling system~ko04071 Sphingolipid signaling pathway~ko04072 Phospholipase D signaling pathway~ko04140 Autophagy - animal~ko04150 mTOR signaling pathway~ko04151 PI3K-Akt signaling pathway~ko04152 AMPK signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04212 Longevity regulating pathway - worm~ko04213 Longevity regulating pathway - multiple species~ko04218 Cellular senescence~ko04360 Axon guidance~ko04361 Axon regeneration~ko04370 VEGF signaling pathway~ko04380 Osteoclast differentiation~ko04510 Focal adhesion~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04611 Platelet activation~ko04620 Toll-like receptor signaling pathway~ko04625 C-type lectin receptor signaling pathway~ko04630 JAK-STAT signaling pathway~ko04650 Natural killer cell mediated cytotoxicity~ko04660 T cell receptor signaling pathway~ko04662 B cell receptor signaling pathway~ko04664 Fc epsilon RI signaling pathway~ko04666 Fc gamma R-mediated phagocytosis~ko04668 TNF signaling pathway~ko04670 Leukocyte transendothelial migration~ko04722 Neurotrophin signaling pathway~ko04725 Cholinergic synapse~ko04750 Inflammatory mediator regulation of TRP channels~ko04810 Regulation of actin cytoskeleton~ko04910 Insulin signaling pathway~ko04914 Progesterone-mediated oocyte maturation~ko04915 Estrogen signaling pathway~ko04917 Prolactin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko04923 Regulation of lipolysis in adipocytes~ko04926 Relaxin signaling pathway~ko04929 GnRH secretion~ko04930 Type II diabetes mellitus~ko04931 Insulin resistance~ko04932 Non-alcoholic fatty liver disease (NAFLD)~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko04960 Aldosterone-regulated sodium reabsorption~ko04973 Carbohydrate digestion and absorption~ko05100 Bacterial invasion of epithelial cells~ko05135 Yersinia infection~ko05142 Chagas disease (American trypanosomiasis)~ko05146 Amoebiasis~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05162 Measles~ko05163 Human cytomegalovirus infection~ko05164 Influenza A~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05169 Epstein-Barr virus infection~ko05170 Human immunodeficiency virus 1 infection~ko05200 Pathways in cancer~ko05203 Viral carcinogenesis~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05211 Renal cell carcinoma~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05218 Melanoma~ko05220 Chronic myeloid leukemia~ko05221 Acute myeloid leukemia~ko05222 Small cell lung cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05231 Choline metabolism in cancer~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~ko05418 Fluid shear stress and atherosclerosis~	,8985,8984,8987,8986,8981,8980,8983,8982,8989,8988,8909,8908,8978,8979,8970,8971,8972,8973,8974,8975,8976,8977,9014,9015,9010,9011,9012,9013,8969,8968,8963,8962,8961,8960,8967,8966,8965,8964,9007,9006,9005,9004,9003,9002,9001,9000,9009,9008,8956,8957,8954,8955,8952,8953,8950,8951,8958,8959,9032,9033,9030,9031,9034,9035,8941,8940,8943,8942,8945,8944,8947,8946,8949,8948,8911,8770,8999,9029,9028,9025,9027,9026,8934,8935,8936,8937,8930,8931,8932,8933,8938,8939,8995,8910,8927,8926,8925,8924,8923,8922,8921,8920,8929,8928,8918,8998,8919,8992,8990,8991,8996,8997,8994,8643,8912,8913,8767,8766,8916,8917,8914,8915,8644,8645,8769,8768	.	,8993	0.999	-0.09	0.402	1.975	prostate
9	98212182	98212182	C	-	PTCH1	exonic	frameshift deletion	ENSG00000185920	.	ENSG00000185920:ENST00000331920:exon21:c.3490delG:p.V1164fs,ENSG00000185920:ENST00000375274:exon21:c.3487delG:p.V1163fs,ENSG00000185920:ENST00000418258:exon21:c.3037delG:p.V1013fs,ENSG00000185920:ENST00000421141:exon21:c.3037delG:p.V1013fs,ENSG00000185920:ENST00000429896:exon21:c.3037delG:p.V1013fs,ENSG00000185920:ENST00000430669:exon21:c.3292delG:p.V1098fs,ENSG00000185920:ENST00000437951:exon21:c.3292delG:p.V1098fs	PTCH1:NM_000264:exon21:c.3490delG:p.V1164fs,PTCH1:NM_001083602:exon21:c.3292delG:p.V1098fs,PTCH1:NM_001083603:exon21:c.3487delG:p.V1163fs,PTCH1:NM_001083604:exon21:c.3037delG:p.V1013fs,PTCH1:NM_001083605:exon21:c.3037delG:p.V1013fs,PTCH1:NM_001083606:exon21:c.3037delG:p.V1013fs,PTCH1:NM_001083607:exon21:c.3037delG:p.V1013fs	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	PTCH1:uc004avk.4:exon21:c.3490delG:p.V1164fs,PTCH1:uc004avl.4:exon21:c.3037delG:p.V1013fs,PTCH1:uc004avm.4:exon21:c.3487delG:p.V1163fs,PTCH1:uc010mro.3:exon21:c.3037delG:p.V1013fs,PTCH1:uc010mrp.3:exon21:c.3037delG:p.V1013fs,PTCH1:uc010mrq.3:exon21:c.3037delG:p.V1013fs,PTCH1:uc010mrr.3:exon21:c.3292delG:p.V1098fs	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	601309	109400;605462;610828;	2162;377;	2162|HPE|Unknown|Multigenic/multifactorial<br>or&nbsp;Not applicable|Neonatal<br>Antenatal|142945 142946 147250 157170 236100 605934 609408 609637 610828 610829 612530 614226 ~377|Basal cell nevus syndrome<br>Gorlin-Goltz syndrome<br>NBCCS<br>Nevoid basal cell carcinoma syndrome|1-9 / 100 000|Autosomal dominant|Adolescent<br>Adult|109400 ~	~ko04024 cAMP signaling pathway~ko04340 Hedgehog signaling pathway~ko04341 Hedgehog signaling pathway - fly~ko04360 Axon guidance~ko05200 Pathways in cancer~ko05205 Proteoglycans in cancer~ko05217 Basal cell carcinoma~	,9111,9110,9113,9112,9114	.	.	.	.	.	.	Nervous_System
12	112888189	112888189	G	A	PTPN11	exonic	nonsynonymous SNV	ENSG00000179295	.	ENSG00000179295:ENST00000351677:exon3:c.G205A:p.E69K,ENSG00000179295:ENST00000392597:exon3:c.G205A:p.E69K	PTPN11:NM_002834:exon3:c.G205A:p.E69K,PTPN11:NM_080601:exon3:c.G205A:p.E69K	clinvar: Likely_pathogenic 	 CancerVar: 10#Likely_pathogenic EVS=[1, 0, 0, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	4.800	24.8	0.002	5.01	0.999	.	.	SH2 domain	PTPN11:uc001ttw.1:exon3:c.G205A:p.E69K,PTPN11:uc001ttx.3:exon3:c.G205A:p.E69K	0.606	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	176876	151100;156250;163950;607785;	86834;648;2499;500;	86834|JMML<br>Juvenile chronic myelomonocytic leukemia|1-9 / 1 000 000|Not applicable|Childhood<br>Infancy|607785 ~648|-|Unknown|Autosomal dominant|Neonatal|163950 605275 609942 610733 611553 613224 613706 615355 616559 616564 ~2499|-|<1 / 1 000 000|Autosomal dominant|Childhood|156250 ~500|Cardiomyopathic lentiginosis<br>Familial multiple lentigines syndrome<br>LEOPARD syndrome|Unknown|Autosomal dominant|Childhood|151100 611554 613707 ~	~ko04013 MAPK signaling pathway - fly~ko04014 Ras signaling pathway~ko04072 Phospholipase D signaling pathway~ko04360 Axon guidance~ko04625 C-type lectin receptor signaling pathway~ko04630 JAK-STAT signaling pathway~ko04650 Natural killer cell mediated cytotoxicity~ko04670 Leukocyte transendothelial migration~ko04722 Neurotrophin signaling pathway~ko04920 Adipocytokine signaling pathway~ko04931 Insulin resistance~ko05120 Epithelial cell signaling in Helicobacter pylori~~ko05130 Pathogenic Escherichia coli infection~ko05168 Herpes simplex virus 1 infection~ko05205 Proteoglycans in cancer~ko05211 Renal cell carcinoma~ko05220 Chronic myeloid leukemia~ko05235 PD-L1 expression and PD-1 checkpoint pathway in cancer~	,9349,9351	.	.	0.987	-2.39	0.740	1.68	skin
18	48591918	48591918	C	T	SMAD4	exonic	nonsynonymous SNV	ENSG00000141646	rs80338963	ENSG00000141646:ENST00000588745:exon5:c.C793T:p.R265C,ENSG00000141646:ENST00000342988:exon9:c.C1081T:p.R361C,ENSG00000141646:ENST00000398417:exon9:c.C1081T:p.R361C	SMAD4:NM_005359:exon9:c.C1081T:p.R361C	clinvar: Pathogenic 	 CancerVar: 12#Pathogenic EVS=[2, 0, 1, 1, 0, 0, 1, 1, 2, 2, 1, 1] 	.	.	.	.	7.642	35	0.0	5.86	1.000	.	.	SMAD domain, Dwarfin-type;SMAD domain-like;SMAD/FHA domain	SMAD4:uc002lfb.4:exon5:c.C616T:p.R206C,SMAD4:uc010xdp.2:exon9:c.C1081T:p.R361C	1.086	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	600993	139210;174900;175050;260350;	1333;2929;2929;329971;2588;	1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~2929|JIP<br>JPS<br>Juvenile gastrointestinal polyposis<br>Juvenile intestinal polyposis|Unknown|Autosomal dominant|Infancy<br>Childhood<br>Adolescent<br>Adult|174900 175050 612242 ~2929|JIP<br>JPS<br>Juvenile gastrointestinal polyposis<br>Juvenile intestinal polyposis|Unknown|Autosomal dominant|Infancy<br>Childhood<br>Adolescent<br>Adult|174900 175050 612242 ~329971|-|Unknown|Autosomal dominant|All ages|174900 ~2588|Facial dysmorphism-intellectual disability-short stature-hearing loss syndrome|<1 / 1 000 000|Autosomal dominant|Childhood|139210 ~	~ko04068 FoxO signaling pathway~ko04110 Cell cycle~ko04310 Wnt signaling pathway~ko04350 TGF-beta signaling pathway~ko04371 Apelin signaling pathway~ko04390 Hippo signaling pathway~ko04520 Adherens junction~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04659 Th17 cell differentiation~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko05161 Hepatitis B~ko05166 Human T-cell leukemia virus 1 infection~ko05200 Pathways in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05220 Chronic myeloid leukemia~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	,9719,9717,9720	.	,9721	1.0	-4.76	0.975	3.485	Colorectal
18	48591881	48591881	-	GCTGTTGCT	SMAD4	exonic	nonframeshift insertion	ENSG00000141646	.	ENSG00000141646:ENST00000588745:exon5:c.756_757insGCTGTTGCT:p.V252delinsVAVA,ENSG00000141646:ENST00000342988:exon9:c.1044_1045insGCTGTTGCT:p.V348delinsVAVA,ENSG00000141646:ENST00000398417:exon9:c.1044_1045insGCTGTTGCT:p.V348delinsVAVA	SMAD4:NM_005359:exon9:c.1044_1045insGCTGTTGCT:p.V348delinsVAVA	clinvar: UNK 	 CancerVar: 6#Uncertain_significance EVS=[2, 0, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	SMAD4:uc002lfb.4:exon5:c.579_580insGCTGTTGCT:p.V193delinsVAVA,SMAD4:uc010xdp.2:exon9:c.1044_1045insGCTGTTGCT:p.V348delinsVAVA	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	600993	139210;174900;175050;260350;	1333;2929;2929;329971;2588;	1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~2929|JIP<br>JPS<br>Juvenile gastrointestinal polyposis<br>Juvenile intestinal polyposis|Unknown|Autosomal dominant|Infancy<br>Childhood<br>Adolescent<br>Adult|174900 175050 612242 ~2929|JIP<br>JPS<br>Juvenile gastrointestinal polyposis<br>Juvenile intestinal polyposis|Unknown|Autosomal dominant|Infancy<br>Childhood<br>Adolescent<br>Adult|174900 175050 612242 ~329971|-|Unknown|Autosomal dominant|All ages|174900 ~2588|Facial dysmorphism-intellectual disability-short stature-hearing loss syndrome|<1 / 1 000 000|Autosomal dominant|Childhood|139210 ~	~ko04068 FoxO signaling pathway~ko04110 Cell cycle~ko04310 Wnt signaling pathway~ko04350 TGF-beta signaling pathway~ko04371 Apelin signaling pathway~ko04390 Hippo signaling pathway~ko04520 Adherens junction~ko04550 Signaling pathways regulating pluripotency of stem cells~ko04659 Th17 cell differentiation~ko04933 AGE-RAGE signaling pathway in diabetic complications~ko05161 Hepatitis B~ko05166 Human T-cell leukemia virus 1 infection~ko05200 Pathways in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05220 Chronic myeloid leukemia~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~	,9719,9717,9720	.	,9721	.	.	.	.	Colorectal
19	1221228	1221228	G	T	STK11	exonic	nonsynonymous SNV	ENSG00000118046	.	ENSG00000118046:ENST00000326873:exon6:c.G751T:p.G251C	STK11:NM_000455:exon6:c.G751T:p.G251C	clinvar: UNK 	 CancerVar: 7#Uncertain_significance EVS=[1, 0, 0, 1, 0, 0, 1, 0, 0, 2, 1, 1] 	.	.	.	.	6.617	32	0.001	4.54	0.951	.	.	Protein kinase domain;Protein kinase-like domain;Serine/threonine/dual specificity protein kinase, catalytic  domain	STK11:uc002lrl.1:exon6:c.G751T:p.G251C	0.989	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	602216	175200;260350;273300;	363483;363494;363504;842;876;99865;1333;2869;	363483|Teratoma of the testis|<1 / 1 000 000|-|-|273300 ~363494|Non-dysgerminomatous germ cell tumor of testis<br>Testicular non seminomatous germ cell tumor<br>Testicular non-dysgerminomatous germ cell tumor|-|-|-|273300 ~363504|Testicular germ cell tumor|-|-|-|273300 ~842|Seminoma of testis<br>Seminomatous germ cell tumor of testis<br>Testicular seminoma|Unknown|Not applicable|Adult|273300 ~876|Endodermal sinus tumor|-|-|-|273300 ~99865|-|Unknown|Unknown|Adolescent<br>Adult|273300 ~1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~2869|Hamartomatous intestinal polyposis<br>PJS<br>Polyps and spots syndrome|1-9 / 1 000 000|Autosomal dominant|Adolescent<br>Adult<br>Childhood|175200 ~	.	,9946,9947,9954,9948,9949,9951,9950,9953,9952	.	.	1.0	-2.36	0.870	3.58	brain
17	7577094	7577105	CTGGAGAGACCG	-	TP53	exonic	nonframeshift deletion	ENSG00000141510	.	ENSG00000141510:ENST00000509690:exon5:c.437_448del:p.146_150del,ENSG00000141510:ENST00000359597:exon7:c.833_844del:p.278_282del,ENSG00000141510:ENST00000269305:exon8:c.833_844del:p.278_282del,ENSG00000141510:ENST00000420246:exon8:c.833_844del:p.278_282del,ENSG00000141510:ENST00000445888:exon8:c.833_844del:p.278_282del,ENSG00000141510:ENST00000455263:exon8:c.833_844del:p.278_282del	TP53:NM_001126115:exon4:c.437_448del:p.146_150del,TP53:NM_001126116:exon4:c.437_448del:p.146_150del,TP53:NM_001126117:exon4:c.437_448del:p.146_150del,TP53:NM_001276697:exon4:c.356_367del:p.119_123del,TP53:NM_001276698:exon4:c.356_367del:p.119_123del,TP53:NM_001276699:exon4:c.356_367del:p.119_123del,TP53:NM_001126118:exon7:c.716_727del:p.239_243del,TP53:NM_000546:exon8:c.833_844del:p.278_282del,TP53:NM_001126112:exon8:c.833_844del:p.278_282del,TP53:NM_001126113:exon8:c.833_844del:p.278_282del,TP53:NM_001126114:exon8:c.833_844del:p.278_282del,TP53:NM_001276695:exon8:c.716_727del:p.239_243del,TP53:NM_001276696:exon8:c.716_727del:p.239_243del,TP53:NM_001276760:exon8:c.716_727del:p.239_243del,TP53:NM_001276761:exon8:c.716_727del:p.239_243del	clinvar: UNK 	 CancerVar: 5#Uncertain_significance EVS=[1, 0, 1, 0, 0, 0, 1, 0, 0, 0, 1, 1] 	.	.	.	.	.	.	.	.	.	.	.	.	TP53:uc002gii.2:exon4:c.356_367del:p.119_123del,TP53:uc010cnf.2:exon4:c.356_367del:p.119_123del,TP53:uc010cng.2:exon4:c.356_367del:p.119_123del,TP53:uc002gih.3:exon7:c.833_844del:p.278_282del,TP53:uc031qyq.1:exon7:c.716_727del:p.239_243del,TP53:uc002gij.3:exon8:c.716_727del:p.239_243del,TP53:uc002gim.3:exon8:c.833_844del:p.278_282del,TP53:uc010cnh.2:exon8:c.833_844del:p.278_282del,TP53:uc010cni.2:exon8:c.833_844del:p.278_282del	.	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	191170	114480;114500;114550;137800;151623;202300;259500;260350;260500;607107;614740;	150;251899;2807;1333;668;1501;524;182067;251627;251630;301;360;94;449;88673;227535;	150|-|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|161550 607107 617075 ~251899|-|1-9 / 1 000 000|Autosomal dominant|Childhood|260500 ~2807|CPP<br>Choroid plexus papilloma|-|-|All ages|260500 ~1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~668|Osteogenic sarcoma|1-9 / 100 000|-|Childhood|259500 ~1501|-|1-9 / 1 000 000|Not applicable|Childhood|202300 ~524|-|1-9 / 100 000|Autosomal dominant|All ages|151623 609265 609266 ~182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~251627|-|-|Not applicable|All ages|137800 616568 ~251630|-|-|Not applicable|Adult|137800 616568 ~301|-|1-9 / 100 000|-|All ages|137800 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~94|Astrocytic tumor|1-9 / 100 000|-|All ages|137800 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04010 MAPK signaling pathway~ko04071 Sphingolipid signaling pathway~ko04110 Cell cycle~ko04115 p53 signaling pathway~ko04137 Mitophagy - animal~ko04151 PI3K-Akt signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04216 Ferroptosis~ko04218 Cellular senescence~ko04310 Wnt signaling pathway~ko04722 Neurotrophin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko05014 Amyotrophic lateral sclerosis (ALS)~ko05016 Huntington disease~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05162 Measles~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05169 Epstein-Barr virus infection~ko05200 Pathways in cancer~ko05202 Transcriptional misregulation in cancer~ko05203 Viral carcinogenesis~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05217 Basal cell carcinoma~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05222 Small cell lung cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05418 Fluid shear stress and atherosclerosis~	,10109,10108,10105,10104,10107,10106,10101,10100,10103,10102,10181,10180,10183,10182,10118,10119,10116,10117,10114,10115,10112,10113,10110,10040,10041,10042,10043,10044,10128,10123,10122,10121,10120,10127,10126,10125,10124,10134,10135,10136,10137,10130,10131,10132,10133,10138,10139,10039,10038,10035,10034,10037,10036,10032,10141,10140,10143,10142,10145,10144,10149,10148,10152,10153,10150,10151,10154,10093,10092,10091,10097,10096,10095,10094,10099,10098,10169,10166,10164,10162,10088,10089,10087,10178,10179,10172,10173,10174,10175,10176,10177	.	,10159,10090,10156,10157,10147,10146,10167,10171,10158,10155,10163,10168,10161,10160,10170,10129,10165,10033,10111	.	.	.	.	Pancreas
17	7578218	7578218	T	C	TP53	exonic	nonsynonymous SNV	ENSG00000141510	.	ENSG00000141510:ENST00000509690:exon3:c.A235G:p.T79A,ENSG00000141510:ENST00000359597:exon5:c.A631G:p.T211A,ENSG00000141510:ENST00000413465:exon5:c.A631G:p.T211A,ENSG00000141510:ENST00000514944:exon5:c.A352G:p.T118A,ENSG00000141510:ENST00000269305:exon6:c.A631G:p.T211A,ENSG00000141510:ENST00000420246:exon6:c.A631G:p.T211A,ENSG00000141510:ENST00000445888:exon6:c.A631G:p.T211A,ENSG00000141510:ENST00000455263:exon6:c.A631G:p.T211A	TP53:NM_001126115:exon2:c.A235G:p.T79A,TP53:NM_001126116:exon2:c.A235G:p.T79A,TP53:NM_001126117:exon2:c.A235G:p.T79A,TP53:NM_001276697:exon2:c.A154G:p.T52A,TP53:NM_001276698:exon2:c.A154G:p.T52A,TP53:NM_001276699:exon2:c.A154G:p.T52A,TP53:NM_001126118:exon5:c.A514G:p.T172A,TP53:NM_000546:exon6:c.A631G:p.T211A,TP53:NM_001126112:exon6:c.A631G:p.T211A,TP53:NM_001126113:exon6:c.A631G:p.T211A,TP53:NM_001126114:exon6:c.A631G:p.T211A,TP53:NM_001276695:exon6:c.A514G:p.T172A,TP53:NM_001276696:exon6:c.A514G:p.T172A,TP53:NM_001276760:exon6:c.A514G:p.T172A,TP53:NM_001276761:exon6:c.A514G:p.T172A	clinvar: Uncertain_significance 	 CancerVar: 9#Likely_pathogenic EVS=[1, 0, 1, 1, 0, 0, 1, 0, 1, 2, 1, 1] 	.	.	.	.	5.096	25.3	0.001	5.41	0.929	.	.	p53, DNA-binding domain;p53-like transcription factor, DNA-binding;p53/RUNT-type transcription factor, DNA-binding domain	TP53:uc002gii.2:exon2:c.A154G:p.T52A,TP53:uc010cnf.2:exon2:c.A154G:p.T52A,TP53:uc010cng.2:exon2:c.A154G:p.T52A,TP53:uc002gio.3:exon3:c.A235G:p.T79A,TP53:uc002gig.1:exon5:c.A631G:p.T211A,TP53:uc002gih.3:exon5:c.A631G:p.T211A,TP53:uc002gin.3:exon5:c.A352G:p.T118A,TP53:uc010vug.3:exon5:c.A514G:p.T172A,TP53:uc031qyq.1:exon5:c.A514G:p.T172A,TP53:uc002gij.3:exon6:c.A514G:p.T172A,TP53:uc002gim.3:exon6:c.A631G:p.T211A,TP53:uc010cnh.2:exon6:c.A631G:p.T211A,TP53:uc010cni.2:exon6:c.A631G:p.T211A	0.996	AFR:.,AMR:.,EAS:.,FIN:.,NFE:.,OTH:.,ASJ:.	191170	114480;114500;114550;137800;151623;202300;259500;260350;260500;607107;614740;	150;251899;2807;1333;668;1501;524;182067;251627;251630;301;360;94;449;88673;227535;	150|-|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|161550 607107 617075 ~251899|-|1-9 / 1 000 000|Autosomal dominant|Childhood|260500 ~2807|CPP<br>Choroid plexus papilloma|-|-|All ages|260500 ~1333|Familial pancreatic cancer|1-9 / 1 000 000|Multigenic/multifactorial|Adult|260350 606856 613347 613348 614320 ~668|Osteogenic sarcoma|1-9 / 100 000|-|Childhood|259500 ~1501|-|1-9 / 1 000 000|Not applicable|Childhood|202300 ~524|-|1-9 / 100 000|Autosomal dominant|All ages|151623 609265 609266 ~182067|Glioma|1-5 / 10 000|-|-|137800 607248 613028 613029 613030 613031 613032 613033 ~251627|-|-|Not applicable|All ages|137800 616568 ~251630|-|-|Not applicable|Adult|137800 616568 ~301|-|1-9 / 100 000|-|All ages|137800 ~360|GBM<br>Glioblastoma multiforme|1-9 / 100 000|Multigenic/multifactorial<br>or&nbsp;Not applicable|All ages|137800 613029 ~94|Astrocytic tumor|1-9 / 100 000|-|All ages|137800 ~449|-|1-9 / 1 000 000|Not applicable|Neonatal<br>Infancy<br>Childhood|114550 ~88673|HCC|1-5 / 10 000|Not applicable|All ages|114550 ~227535|Familial breast cancer<br>Familial breast carcinoma<br>Hereditary breast carcinoma|-|-|-|114480 600048 604370 605365 612555 613399 ~	~ko01522 Endocrine resistance~ko01524 Platinum drug resistance~ko04010 MAPK signaling pathway~ko04071 Sphingolipid signaling pathway~ko04110 Cell cycle~ko04115 p53 signaling pathway~ko04137 Mitophagy - animal~ko04151 PI3K-Akt signaling pathway~ko04210 Apoptosis~ko04211 Longevity regulating pathway~ko04216 Ferroptosis~ko04218 Cellular senescence~ko04310 Wnt signaling pathway~ko04722 Neurotrophin signaling pathway~ko04919 Thyroid hormone signaling pathway~ko05014 Amyotrophic lateral sclerosis (ALS)~ko05016 Huntington disease~ko05160 Hepatitis C~ko05161 Hepatitis B~ko05162 Measles~ko05163 Human cytomegalovirus infection~ko05165 Human papillomavirus infection~ko05166 Human T-cell leukemia virus 1 infection~ko05167 Kaposi sarcoma-associated herpesvirus infection~ko05168 Herpes simplex virus 1 infection~ko05169 Epstein-Barr virus infection~ko05200 Pathways in cancer~ko05202 Transcriptional misregulation in cancer~ko05203 Viral carcinogenesis~ko05205 Proteoglycans in cancer~ko05206 MicroRNAs in cancer~ko05210 Colorectal cancer~ko05212 Pancreatic cancer~ko05213 Endometrial cancer~ko05214 Glioma~ko05215 Prostate cancer~ko05216 Thyroid cancer~ko05217 Basal cell carcinoma~ko05218 Melanoma~ko05219 Bladder cancer~ko05220 Chronic myeloid leukemia~ko05222 Small cell lung cancer~ko05223 Non-small cell lung cancer~ko05224 Breast cancer~ko05225 Hepatocellular carcinoma~ko05226 Gastric cancer~ko05230 Central carbon metabolism in cancer~ko05418 Fluid shear stress and atherosclerosis~	,10109,10108,10105,10104,10107,10106,10101,10100,10103,10102,10181,10180,10183,10182,10118,10119,10116,10117,10114,10115,10112,10113,10110,10040,10041,10042,10043,10044,10128,10123,10122,10121,10120,10127,10126,10125,10124,10134,10135,10136,10137,10130,10131,10132,10133,10138,10139,10039,10038,10035,10037,10036,10032,10141,10140,10143,10142,10145,10144,10149,10148,10152,10153,10150,10151,10154,10093,10092,10091,10097,10096,10095,10094,10099,10098,10169,10166,10164,10162,10088,10089,10087,10178,10179,10172,10173,10174,10175,10176,10177	.	,10159,10090,10156,10157,10147,10146,10167,10171,10158,10155,10163,10168,10161,10160,10170,10129,10165,10033,10111	0.978	-6.73	0.988	2.61	lung
